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γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the vertebrate
central nervous system. GABA exert its inhibitory action mainly via the γ-Aminobutyric
acidA receptors (GABAARs), which are ligand-gated ion channels consisting of several
classes of subunits (α, β, γ, δ, ε and π). These subunits may assembly into, at least, 10
major GABAA receptor subtypes in the brain. GABAAR is known to contain several
modulatory binding sites for pharmacologically and clinically important drugs such as
benzodiazepines (BZD), barbiturates, neurosteroids and ethanol, with the BZD binding
site as the most important one. The anxiolytic, anticonvulsant, muscle relaxant and
sedative-hypnotic BZDs are among the most prescribed drugs clinically. Because of the
side effects associated with the use of classical BZDs e.g. diazepam and flunitrazepam,
two strategies have been generally adopted in development of new generation of
anxiolytics. One is to develop BZD receptor partial agonist; the other is to develop BZD
receptor subtype selective compounds. The in vitro radioligand receptor binding assays
performed on various brain tissues and a variety of recombinant GABAAR subunit
combinations expressed in various cell lines has been well established. So was the
electrophysiological method such as the patch-clamp technique performed on different
recombinant GABAAR subtypes. These methods make it possible to screen and
characterise compounds with partial agonistic or subtype selective properties from
various sources. Due to the known allosteric interaction between the various existing
binding sites on the GABAARs, by applying these methodologies mentioned above, it is
also possible to discover compounds binding to additional allosteric binding sites on the
GABAARs. The identification of these new sites might be useful as an important tool
for the investigation of the interaction of known binding sites, as well as a potential
target for new drugs.
The aim of this project is to isolate and characterise active compounds from medicinal
plants used in traditional Chinese medicine (TCM) for binding sites on the GABAARs.
The studies will focus on the BZD binding sites.
Totally ca. 50 TCM plants were screened mainly for their binding activity (GABA,
BZD and TBPS binding sites) on the GABAARs (some of the plants have also been
tested against the kainate receptor). Activities were found in extracts of 13 plants. 12
4active compounds from 7 plants were purified and chemically elucidated. Because of
the lower affinity (Affinity is the property of attraction of a drug for a receptor. It is
numerically represented by the equilibrium dissociation constant (KD) of the ligand-
receptor complex) found in the initial experiments, some of the active compounds
(acacetin, rutaecarpine) were not investigated further.
The furanocoumarin derivatives phellopterin, byakangelicol and imperatorin were
purified from Angelica dahurica. Phellopterin, the most potent derivative, was found
inhibiting [3H]diazepam and [3H]Ro 15-1788 binding to the BZD binding site of the rat
brain GABAAR in vitro with IC50 values (Concentration of the compound induces 50%
inhibition of the radio-ligand receptor binding) of 400 and 680 nM, respectively.
Scatchard plot analysis showed that phellopterin increased the KD (Constant of
dissociation) without changing the Bmax (Number of maximum binding sites) in
[3H]diazepam binding to various rat brain membrane preparations. This indicates that
phellopterin induced a competitive inhibition of [3H]diazepam binding. The GABA
ratios (The ratio of the IC50 values determined for the testing compound in absence and
presence of GABA (usually 100 µM) in the [3H]BZD binding assays) of 1.3 for
[3H]diazepam binding and 1.7 for [3H]Ro 15-788 binding indicate that phellopterin is a
partial agonist at the BZD site. This finding was supported by TBPS shift experiments
(TBPS shift (or TBPS ratio) is calculated as the ratio of the specific binding of
[35S]TBPS ) in the presence and absence of testing compound in a on-rate experiment).
The partial agonistic profile of phellopterin makes it an interesting candidate for further
development of more potent derivatives.
Honokiol and magnolol were purified from Magnolia officinalis. They are previously
reported having central depressant effects such as: sedation, ataxia, muscle relaxation as
well as having anxiolytic activity in animal experiments, but the mechanism of action
remains unknown. Our data shows that both honokiol and magnolol enhance
[3H]muscimol binding to rat brain membrane preparations and to various human
recombinant GABAAR subtypes expressed in Sf9/baculovirus system. Saturation
binding assays showed that honokiol and magnolol increased the Bmax for [3H]muscimol
binding to GABAARs constructed by α2β3γ2S and α2β3 subunit combinations. However,
both the Bmax and the KD for [3H]muscimol binding to α1β2γ2S and α1β2 subunit
combinations were increased by honokiol and magnolol. The results indicate that
5honokiol and magnolol exert different affinities for different GABAAR subtypes.
Honokiol and magnolol (10 µM) potentiated GABA-induced chloride current in whole-
cell patch clamp experiments comparable to that of diazepam. Our data suggest that
honokiol and magnolol by interacting with the receptor complex could change the
neuronal transmission mediated by GABA through GABAARs. This effect could
partially explain their anxiolytic and central depressant effects previously reported. The
interaction of honokiol and magnolol with GABAARs may be explained by binding to a
new unknown binding site. The binding of honokiol and magnolol to these allosteric
sites may convert the low affinity GABA binding sites to the high affinity sites, which
can be detected by [3H]muscimol binding assays.
The synthetic or semi-synthetic derivatives of natural-occurring compounds take a great
part of the total nature-originated drugs. Therefore, based on the available data of
nature-occurring compounds to investigate their synthetic or semi-synthetic derivatives
for a possible activity would be a natural consideration.
Many flavonoids, such as apigenin, chrysin and amentoflavone, have been purified from
plants and shown previously to bind to BZD receptors in the Central nervous system
(CNS) in vitro. In the present communication screening of 32 commercially available
flavonoids, seventeen structurally related flavonoid derivatives were found to inhibit the
binding of [3H]diazepam to GABAA/BZD receptors. 6-methylflavone, the most potent
one (IC50 value of 120 nM) was characterised by binding as well as functional assays.
Saturation binding experiments showed that 6-methylflavone is a competitive inhibitor
of [3H]Ro 15-1788 binding to rat cortical GABAA/BZD receptors. Data was obtained
for the GABA ratios of [3H]diazepam binding to various rat brain membrane
preparations in the presence of increasing concentrations of 6-methylflavone. Data was
also accumulated for the GABA ratios of [3H]Ro 15-1788 binding to various
recombinant human GABAA/BZD receptor subunit combinations expressed in
baculovirus/Sf9 insect cell system in the presence of increasing concentrations of 6-
methylflavone. Both these types of data were compared with data obtained by assay of
the currents assays by the whole-cell patch clamp on Sf-9 insect cells. It was concluded
that 6-methylflavone is most likely a antagonist on the BZD binding site. Meanwhile,
based on available data, some general structure-activity relationship of flavonoids for
their inhibitory effect on the GABAA/BZD receptor has been discussed.
6β-carboline-3-carboxylic acid methyl ester (βCCM) and β-carboline-3-carboxylic acid
ethyl ester (βCCE) have been isolated from Pseudostellaria heterophylla with trace
amount. Pseudostellaria heterophylla was chosen from a well-known TCM prescription
named Panacea anti-epilepsy. As seen in the separation process on HPLC, there are at
least 10 or more active substances that show inhibition of [3H]flunitrazepam binding
with similar potency in-vitro. Both βCCM and βCCE are known as potent
proconvulsant acting on GABAA/BZD receptor complex. The plant is used in the
reverse pharmacological direction as an anti-convulsant treatment in TCM. This raised
the intriguing possibility that some other β-carboline derivatives or other compounds
having anti-convulsant property may present in this plant. To our knowledge, this is the
first report demonstrating a plant origin of these β-carboline-3-carboxylic acid
derivatives.
Finally, based on our own experiences in the isolation and characterisation of
compounds from medicinal plants, some possible pitfall was also discussed.
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γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the vertebrate
central nervous system (CNS). Depending on the brain region, 20 to 50% of all central
synapses use GABA as the transmitter (Young and Chu, 1990; Halasy and Somogyi,
1993). GABA mediates inhibitory action throughout the CNS by activating three classes
of receptors, GABAA, GABAB and GABAC receptors that are classified structurally and
pharmacologically (Table 1). A new classification of GABAARs has recently been
proposed by Barnard et al. (1998). GABAARs consist of several classes of subunits (α,
β, γ, δ, ε and π) that form a integrated chloride ion channels (for review, see Dunn, et al.
1994; Smith and Olsen, 1995; Davies, et al. 1996). Each subunit possesses extracellular
N and C terminal domains and four transmembrane regions. GABAARs contain
modulatory binding sites for benzodiazepine (BZD), barbiturates, neurosteroids and
ethanol, are activated by GABA, muscimol and inhibited by bicuculline and picrotoxin
(reviewed by Braestrup and Nielsen, 1983; Macdonald and Olsen, 1994; Rabow et al.,
1995; Sieghart, 1995; Johnston, 1996a; Doble and Martin, 1996; Krogsgaard-Larsen et
al., 1997; Hevers and Lüddens, 1998). In contrast, GABAB receptors are members of the
seven transmembrane receptor family, which are coupled to either K+ or Ca 2+ channels
via G-proteins and are regulated by intracellular second messenger systems (reviewed
by Bowery, 1989, 1993; Mott and Lewis, 1994; Malcangio and Bowery, 1995; Misgeld
et al, 1995). Two splice variants of GABAB receptor subunits GABAB R1a and GABAB
R1b were recently cloned that showed sequence similarity to the metabotropic receptors
for the excitatory neurotransmitter L-glutamate (Kaupmann et al. 1997; Bettler et al.
1998). GABAB receptors are selectively activated by GABA and (-)baclofen and are
inhibited by phaclofen. Although similar to GABAARs directly associated with a Cl- ion
channel, GABAC receptors differ markedly from GABAA and GABAB receptors in their
pharmacological properties. They are insensitive to both bicuculline and baclofen as
well as to GABAAR modulatory drugs like BZDs, barbiturates or neurosteroids, but
stimulated by GABA and certain analogues of GABA, such as cis-4-aminocrotonic acid
(CACA). GABAC receptors are though to be composed of the ρ subunits (ρ1-3 and two
splicing variants of ρ1) and are predominantly expressed in the vertebrate retina
(reviewed by Bormann and Feigenspan, 1995; Johnston, 1996b; Lukasiewicz, 1996;
8Enz and Cutting 1998; Feigenspan and Bormann, 1998; Martinez-Torres et al., 1998).
Table 1 summarises the main differences among these three receptor systems.
Table 1. A brief summary of different GABA receptors
Receptors GABAA GABAB GABAC
Ion channels Ionotropic Cl- Metabotropic G
protein-coupled K+
Ionotropic Cl-
Protein subunits α1-6, β1-4, γ1-4, δ, ε
and π
R1a, R1b ρ1-3
Agonists GABA
Muscimol
GABA
(-)baclofen
GABA
CACA
Antagonists Bicuculline
Picrotoxin
Phaclofen
Saclofen
3-APA
3-APPA
Allosteric
modulator
BZDs, barbiturates,
neurosteroids etc
No No
Receptor
structure
Hetero-oligomeric
pentamers, each
subunit with 4
transmembrane
domains
7 transmembrane
domains couple
with G-protein
Homo-oligomeric
pentamers, each
subunit with 4
transmembrane
domains.
Primary locations Frontal cortex,
cerebellar granule
cell layer, olfactory
bulb etc.
Cerebellar
molecular layer,
frontal cortex,
thalamic nuclei.
Retina
This thesis concerns only the GABAARs.
The aim of this project is to isolate and characterise active compounds from medicinal
plants used in traditional Chinese medicine (TCM) for the existing binding sites on the
GABAARs, with a focus on the BZD binding sites. There are several factors contribute
to the initiation of the current project: 1). The establishment and routinisation of the
radioligand-receptor binding assays for the agonists (e.g. GABA and muscimol) and the
modulatory agents (e.g. BZDs and TBPS) of the GABAAR provides a fast simple
9screening and characterising system for novel potential ligands from various sources,
including medicinal plants. 2). The diversity of the subunit isoforms leads to a variety of
different GABAAR subtypes that show differential expression in various neuronal
populations. This diversity could potentially mediate affinities of specific drugs. With
the variety of GABAAR subtypes, the possibility exists to target compounds to a
specific GABAAR subtype and thereby avoid side effects associated with the use of
classical BZDs. The establishment of cell lines expressing individual recombinant
receptor subtypes (both for binding as well as for electrophysiological studies) provides
the opportunity of developing such specific subtype-selective compounds which in turn
might be a useful tool for the characterisation of the physiological role of individual
GABAAR subtypes in vivo. 3). In order to obtain drugs with new molecular structures
and pharmacological profiles, it is necessary to isolate and identify compounds by
bioassay-guided fractionation from natural products, especially medicinal plants used in
folkloric or traditional medicine, like TCM. TCM and herbs have been widely used in
China and outside Chinese communities for thousands years. Throughout the long
Chinese history, there has been an accumulation of experience using medicinal plants to
treat a variety of diseases. TCM plays a role in the health care of Chinese people
through the history, as well as in the modern times. Using modern analytical methods
and assay systems, new drugs (single compound drugs, such as artemisinin) have been
isolated from Chinese medicinal plants (Xiao, 1983; Qin and Xu, 1998).
It is my desire and belief that the combination of my previous knowledge of TCM (11
years from 1983 ∼ 1994) with the knowledge from this laboratory on the GABAARs
will lead to the identification of some interesting active compounds for the
GABAA/BZD receptor system from Chinese medicinal plants.
Within this thesis, the first two sections will focus on the pharmacology and molecular
biology of the GABAA/BZD receptors. The third section will discuss natural products as
a source of new drugs and pharmacological tools in general, and the general status of
TCM and TCM medicinal plants. The fourth section will present the experimental work
and the results in identification and characterisation of active compounds from Chinese
medicinal plants and semi-synthetic compounds with nature origin to the GABAA
receptors. Based on our own experiences, some possible pitfall will also be discussed.
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Section 1. Pharmacology of GABAARs
1.1. GABA binding site
GABAARs are ligand-gated Cl- channels. Its neurotransmitter GABA is a small amino
acid (AA) derived from glutamate by glutamic acid decarboxylase. Activation of
GABAARs by GABA results in an increase in neuronal membrane conductance for Cl-
from the prolonged openings of the ion channels, this influx of Cl- causes a localised
hyperpolarisition of the neuronal membrane, which counteracts the effects of
depolarising stimuli and results in the inhibition of synaptic transmission (Macdonald
and Twyman, 1992). The inhibitory action of GABA can be mimicked by full agonists,
such as muscimol (a natural product from the mushroom Amanita muscaria),
competitively antagonised by competitive antagonists, such as bicuculline (another
natural product isolated from the plant Dicentra cucullaria and a variety of Corydalis,
Dicentra and Adlumia species), and noncompetitively antagonised by picrotoxin (an
equimolar mixture of picrotoxinin and picrotin isolated from Anamirta cocculus and
related poisonous plants). The GABA binding sites on the GABAAR complex in
mammalian brain have been characterised in homogenates of various membrane
preparations used in specific radioligand-receptor binding assays. There seems to be
three different GABA binding sites: 1). the high affinity binding site, 2). the low affinity
recognising sites and 3). the very low affinity binding site. These sites have been
experimentally characterised. Thus, homogenisation, multiple wash steps, the use of
sodium-free buffer and incubation at 0 °C serves to remove endogenous GABA and
other potential endogenous ligands and to disable the GABA transport system are
necessary steps for characterisation of these sites (Braestrup and Nielsen, 1983).
[3H]GABA and [3H]muscimol binding studies in mammalian brain tissue have revealed
that both high (KD values in low nanomolar range) and low affinity (KD values in high
nanomolar range) states of GABAARs for GABA exist (Olsen et al., 1981). The low-
affinity recognition site can be specifically labelled by the specific GABA antagonist
bicuculline, thus this site may be an antagonist-preferring binding sites (Olsen and
Snowman, 1983). The fact that micromolar concentrations of GABA are needed to open
Cl- channels in ion flux, electrophysiological experiments and to modulate other binding
sites (e.g. BZD sites) on the GABAAR complex, suggest GABA probably exerts its
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physiological effects by acting at an additional very low affinity-binding site (KD values
in micromolar range), which can only be opened during synaptic transmission when
GABA is massively released into the synaptic cleft (reviewed by Sieghart, 1992; 1995).
The apparent separate existence of high, low, very low affinity binding sites for GABA
can be explained either in terms of different conformational states of the same receptor,
or in term of distinct GABA binding sites on a single GABAAR (Sieghart, 1995).
Table 2. GABAAR agonists, partial agonists and antagonists∗
Agonists
Endogenous GABA, Taurine and β-alanine
Exogenous Muscimol, THIP, Isoguvacine, ZAPA, (+)-TACP
Partial Agonist 4 –PIOL, Thio-THIP
Antagonists
Competitive Bicuculline, Bicuculline methochloride, SR95531, RU5135,
Pitrazepin, Securinine, (+)-Hydrastine, Benzyl penicillin, (+)-
Tubocurarine
Noncompetitive Picrotoxin, δ-guanidinovaleric acid, Cunaniol, Dimefline,
Enoxacin, m-Benzenesulfonic acid diazonium chloride, Dopamine
sulfate, Norfloxacin, Pentylenetetrazole, Furosemide
∗ Data is based on papers (Kerr and Ong, 1992; Johnston, 1996a; Krogsgaard-Larsen et
al. 1997).
Structurally different compounds are known to interact with the GABA binding site
within the GABAAR complex as agonist, partial agonist and antagonist (Table 2). Since
the specific receptor antagonists are essential tools for the characterisation of the
physiological and pharmacological properties of receptors, the discovery of the
convulsant alkaloid bicuculline as an antagonist of the inhibitory action of GABA in the
CNS provided a vital pharmacological tool to probe GABA mediated inhibition. The
GABAAR agonists may induce rapid desensitisation and the antagonists are potential
anxiogenic, proconvulsant or convulsant compounds (Krogsgaard-Larsen et al., 1997).
There is considerable interest in GABAA partial agonists as targets for drug
development. Partial agonists of GABAARs, particularly those of relatively low
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efficacy, such as Thio-THIP and Thio-4-PIOL are promising therapeutic agents for
Alzheimer’s disease (Krogsgaard-Larsen et al., 1994, 1997).
1.2. BZD binding site (BZD receptors)
The most notable phenomenon of GABAARs is that they possess a variety of allosteric
binding sites (allosteric binding sites are referred to the binding sites that are different
from the agonist binding sites within the receptor complex, binding of the
corresponding compounds to these sites mediate a different biological response from the
agonist) for several clinically important drugs. The activation of these sites often result
in an allosteric modulation on the activity of agonists. The most widely investigated
allosteric modulatory sites are the BZD sites (Lüddens et al., 1995; Rabow et al., 1995;
Sieghart, 1995). BZDs were introduced as clinical therapeutic agents in the early 1960s
before GABA was considered as a neurotransmitter. The first clue of the action of
BZDs was the proposal that BZDs facilitate GABA-mediated synaptic inhibition (Costa
et al., 1975; Haefely et al., 1975; Polc and Haefely, 1976). However, it was the
discovery of high-affinity binding sites in vertebrate brain that started the exiting
exploration on understanding of the pharmacological actions of BZDs (Squires and
Braestrup, 1977; Möhler and Okada, 1977). The binding of BZDs to these sites was
stimulated by GABA (Tallman et al., 1978). Because there was a excellent correlation
between the clinical potency of BZDs and their affinity for these binding sites, it is now
believed that these GABAAR-associated binding sites are the pharmacological receptors
by which the BZDs exert their clinically important actions (Haefely et al., 1985). That is
why the BZD binding sites were termed BZD receptors (Braestrup and Nielsen, 1983).
1.2.1. BZD receptor subtypes and ligand selectivity
1.2.1.1. Central against peripheral
BZD receptors can be divided into two classes: “central” and “peripheral” receptors,
referring to the receptors appeared in CNS and peripheral tissues as kidney,
respectively. Flumazenil (Ro 15-1788) only interacts with the “central” receptors, while
Ro 5-4868, the 4’-chloro derivative of diazepam, is a selective ligand for the
“peripheral” receptors. Only the central BZD receptors are associated with GABAARs.
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1.2.1.2. BZD receptor subtypes and the selectivity of ligands
Most BZDs bind to the central BZD receptors with similar affinities throughout the
brain, but the binding properties of several compounds, most notably CL 218872
(Squires et al., 1979; Sieghart, 1983) and β-carboline-3-carboxylic acid ethyl ester
(βCCE) (Nielsen and Braestrup, 1980) demonstrate the heterogeneity of BZD receptors.
Two types of BZD receptor were originally proposed based on their pharmacology and
distribution. The BZD1 subtype found throughout the brain but predominant in the
cerebellum scarcely in the hippocampus (Faull et al., 1987; Faull and Villiger, 1988;
Olsen et al, 1990; Lüddens et al., 1995), show high affinity to the triazolopyridazine CL
218872, and βCCE (β-carboline-3-carboxylic acid ethyl ester)  (Squires et al., 1979;
Braestrup and Nielsen, 1980; Nielsen and Braestrup, 1980; Sieghart, 1983). The BZD2
subtype found principally in hippocampus, spinal cord and cortex show low affinity for
these ligands mentioned above and high affinity for flunitrazepam. A third class of BZD
receptor was found in cerebellar granule cells, associated with the α6 GABAAR subunit,
is insensitive to the prototype BZDs e.g. diazepam. It probably functionally involves in
mediating the alcohol-induced impairment in motor performance that can be
antagonised by the selective ligand Ro 15-4513 (Sieghart et al., 1987; Lüddens et al.,
1990). Molecular biology studies have demonstrated that several isoforms of the α
subunit of the GABAAR exist, and the phenotype of the BZD binding site depended on
the nature of the α subunit expressed in the receptor (Levitan, et al 1988; Pritchett, et al
1989). This molecular biological basis for the heterogeneity of BZD receptor subtypes
will be discussed in detail in Section 2.5.1.
The functional role for the individual BZD receptor subtype was for several years
unclear due to the relative low selectivity of available compounds (Doble and Martin,
1996). Thus, compounds with higher selectivity for the different BZD receptor subtypes
would be desirable as pharmacological tool for the characterisation of the functional
properties of BZD receptor subtypes, as well as a lead for development of new
pharmaceuticals avoiding the side effects associated with the classical BZDs.
1.2.2. Intrinsic efficacy of BZD receptor ligands and partial agonism
Intrinsic efficacy is the inherent ability of a given compound to initiate a biological
response. It is the property that a ligand induces the conformational change of its
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receptor and changes the behaviour of the receptor toward other proteins in the
membrane, (Kenakin and Kenakin, 1997).  For the BZD receptors, generally, there are
three classes of ligands, agonist, antagonist and inverse agonist with different efficacy.
1.2.2.1. Full agonist and partial agonist
Most of the prototypical 1,4-benzodiazepines appear to be agonists at the BZD receptors
(For chemical structure, see Section 1.2.3.; Gardner et al., 1993). Electrophysiological
experiments in many different neuronal systems have indicated that BZDs such as
diazepam, enhance the actions of GABA at the GABAAR by facilitating its binding to
the receptor and by increasing the frequency of Cl- channel opening (Study and Barker,
1981; Edgar and Schwarz, 1992). However, they do not open Cl- channels in the
absence of GABA (Study and Barker, 1981; Polc, 1988). The principal behavioural
effects of classical BZDs in animals are anxiolytic, anticonvulsant, sedative and
myorelaxant effect (Doble and Martin, 1996). Clinically, the sedative/myorelaxant
effects together with amnestic effect, tolerance and withdrawal effect are generally
considered as unwanted side-effects (Haefely et al., 1990; Doble and Martin, 1992).
Studies with BZD full agonists have demonstrated that higher doses BZDs and higher
occupancy of the BZD receptors are required to produce sedative/myorelaxant effects
than, but not for producing of anticonvulsant and anxiolytic effects (Braestrup and
Nielsen, 1986; Petersen et al., 1986, Petersen, 1987). Since partial agonists have lower
intrinsic efficacy, they do not activate all the receptors they occupied. For partial
agonists of sufficiently low efficacy, it may be impossible for them to activate sufficient
receptors to induce sedative/myorelaxant effects even at high doses that would be
enough to occupy the receptors completely (Haefely, 1994; Doble and Martin, 1996;
Figure 1).
15
Figure 1.
Figure 1. Theoretical receptor activation curves for ligands on BZD receptors.
Because of the different intrinsic efficacy, at the some administered dose (Upper
diagram) or the same amount of receptor occupied (Lower diagram), BZD receptor
partial agonists activate much less portion of the receptor they occupied, thus can only
induce certain behavioural effects, e.g. anxiolytic effect (Modified from Doble and
Martin, 1996).
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1.2.2.2 Antagonists
 Ro 15-1788 (flumazenil) was the first one identified as a reference neuronal BZD
receptor antagonist (Hunkeler et al., 1981). It has nanomolar affinity (KD) for the BZD
receptors, without BZD-like behavioural properties (anxiolytic, anticonvulsant, sedative
and muscle relaxation etc.). It has been shown to potently antagonise the acute central
effects of BZD receptor agonists, partial agonists and inverse agonists (Haefely, et al.,
1983; Brogden and Goa, 1991). Clinically, flumazenil is principally used for the
reversal of BZD-induced sedation/anaesthesia on patients undergoing surgical
procedures and in the treatment of overdose with BZDs (Gardner, et al., 1993; Malizia
and Nutt, 1995; Upton and Blackburn, 1997; Weinbroum et al., 1997).
1.2.2.3 Inverse agonists and partial inverse agonists
The β-carboline derivatives were discovered in attempts to isolate endogenous ligands
for BZD receptors. The βCCE was isolated from ethanol treated human urine at low pH
(Nielsen, et al., 1979; Braestrup, et al., 1980). Although subsequently βCCE was shown
to be an artefact formed during the isolation procedure by an ethanol esterification of β-
carboline-3-carboxylic acid, which possibly derived from tryptophan by a ring closure
(Kerr and Ong, 1992). βCCE has been used as a lead structure for the development of
psychotropic drugs (e.g. abecarnil) as well as a biological tools (e.g. full inverse agonist
methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM)) for the research of
GABAA /BZD receptor complex. The behavioural effects of these compounds are the
opposite of those effects produced by classical BZDs, which include anxiogenic,
proconvulsant or convulsant effects.  This resulted in the concept of “inverse agonist”,
in contract to the prototypical BZD agonists. The BZD receptor was the first and for
many years the only receptor at which bi-directional (both agonistic and inverse
agonistic) efficacy was observed (Braestrup et al., 1983, 1984). In addition to their own
intrinsic pharmacological activity, inverse agonists can potently reverse the effects of
BZD full agonists (Oakley and Jones, 1980; Tenen and Hirsch, 1980; Cowen, et al.,
1981). As partial agonists can antagonise the action of full agonists, partial inverse
agonists can also block convulsions evoked by full inverse agonists, such as DMCM
(Oakley and Jones, 1982; Corda, et al., 1989). Therapeutic opportunities for inverse
agonists were limited due to proconvulsant effect. However, a very weak inverse
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agonist that is devoid of proconvulsant activity may be of potential value for enhancing
memory function due to their behavioural arousal effect. Thus, these compounds might
be useful for the treatment, for example, of Alzheimer’s disease (Jensen et al., 1987;
Forster et al., 1995; Upton and Blackburn, 1997).
1.2.2.4 Efficacy spectrum of BZD receptor ligands
From the above overview, it is apparent that the pharmacological profile of BZD
receptor ligands cover a wide spectrum of intrinsic efficacy, stretching from full
agonists (anxiolytic, anticonvulsant and sedative compounds), partial agonists, over
antagonists, to partial inverse agonists and inverse agonists (anxiogenic, proconvulsant
substances) (Figure 2).
Figure 2.
Figure 2. Spectrum of intrinsic efficacy of BZD receptor ligands and their
pharmacological properties. The intrinsic efficacy is assigned + 1.0 for full agonists, 0
for competitive antagonists, and – 1.0 for full inverse agonists. The representative
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ligands with diverse intrinsic efficacy from BZD class were shown (Modified from
Schmiechen et al., 1993; Haefely, 1994).     
In addition to the BZD and β-carboline series, there are some other structural unrelated
groups of compounds acting on the BZD receptors with differential pharmacological
activities (for details, see Section 1.2.3.). Some of these compounds are of natural origin
(for review, see Ai et al., 1997b).
1.2.3. BZD receptor ligands
The discovery of the high affinity binding sites of BZDs in the brain and the
development of radioligand binding assays proved valuable for the later discovery of
various ligands with diverse chemical structures, and for the structure-activity
relationship studies at the BZD recognition site. This section will just give a brief
overview of representative ligands with different intrinsic efficacy from distinct
chemical groups. For comprehensive review, see Braestrup and Nielsen, 1983; Haefely
et al., 1985; Gardner, 1988; Gardner et al., 1993; Gupta, 1995; Doble and Martin, 1996.
1.2.3.1. BZD analogues
Figure 3.
7-position: NO2 > CF3 > Br > CN > Cl > N(CH3)2 > SOCH3 > SBu > SCH3 > CH3 > H >
SO2CH3 > Ph > F
2’-position: Cl > F > Br > NO2 > CF3 > H > OCH3 > CH3
Figure 3. The chemical structure of 1,4-BZDs, and the rank orders for the
individual group contributions to activity against pentetrazol induced seizure at
the 7- and 2’-positons (Modified from Gupta, 1995)
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Studies of the structure-activity relationship have suggested that the presence of the
seven membered ring (B) is essential for activity and that substitution is advantageous
for activity only at positions 1, 3, 7 and 2’. At position 7-, the nitro group is the most
effective substitution and fluorine the least; at position 2’- the halogen substitution leads
to compounds with increased affinity (Figure 3, for review see Haefely et al., 1985;
Gupta, 1995; Doble and Martin, 1996). The carbonyl group at position 2 is important
for binding activity; its removal results in a decrease in affinity by two orders of
magnitude. Saturation of the 4,5 double bond results in complete loss of in vitro activity
(Haefely et al., 1985; Doble and Martin, 1996). Most interestingly, the chemical
modification of imidazobenzodiazepines (e.g. Ro 15-4513 and Ro 15-1788) have lead to
ligands binding selectively to α5-containing subtype of the GABAARs with inverse
agonistic activity (KI value for α5β2γ2 subtype was shown under the chemical structure
of these compounds. For all other subtypes (α1, α2, α3 and α6 combined with β2γ2) the
KI values (KI is the dissociation equilibrium constant for an inhibitor, it can be
calculated from IC50 from the Cheng-Prusoff correction formula KI = IC50/(1+[L]/KD),
in which [L] is the concentration of the testing ligand, KD is the dissociation equilibrium
constant of the radioligand, Haylett, 1996) are greater than 300 nM (Zhang, et al.,
1995). Based on the basic structure, many derivatives of BZDs are produced. Some
representative ones are presented (Figure 4).
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Figure 4.
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Antagonist
                                      Ro 15-1788 (flumazenil)
Partial inverse agonists
          Ro 15-4513                      Ro 16-0154                               Ro 15-3505
Full inverse agonists
                                                      Ro 19-4603
α5-containing subtype selective compounds
KI  40 nM                                        80 nM                                              30 nM
Figure 4. The representative BZDs with diverse intrinsic efficacy
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1.2.3.2. β-carbolines
Some general rules were obtained during the structural optimisation of β-carbolines, and
a refined lead structure more suitable for optimisation could be described as: 1) A full
aromatic plane of β-carboline structure. 2) No substitution in positions 1,8 and 9. 3) A
metabolically stable ester group in position 3 (e.g. oxadiazole in ZK 95276). 4) Open to
a wide range of substitution in position 5 and 6. 5) Limited freedom of substitution in
position 4 and 7 (Schmiechen et al., 1993; Figure 5).
The pharmacological profile of β-carboline derivatives covers a entire activity
spectrum, ranging from full agonists (anxiolytic, anticonvulsant, sedative compounds),
partial agonists, antagonists, to inverse agonists (anxiogenic, proconvulsant substances)
with the inverse agonist as predominant (Gardner et al., 1993; Figure 6).
Figure 5.
A
                               The basic structure of β-carbolines
B
Figure 5. A: The basic structure of β-carbolines. B: The allowed and prohibited
substitutions of the β-carboline structure (B, modified from Schmiechen et al., 1993)
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Figure 6.
Full agonists
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Partial agonists
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Full inverse agonists
             RU 33973                                                               DMCM
Figure 6. The representative β-carbolines with diverse intrinsic efficacy
1.2.3.3. Imidazoquinolines and imidazopyrimidines
A large number of imidazoquinolines and imidazopyrimidines have been synthesised
which show affinity for BZD receptors. Among these compounds, because of its partial
agonistic profile, RU 32698 (divaplon) was selected as a candidate for clinical
development having the optimum profile for use as a potential non-sedative anxiolytic
(Gardner et al., 1993). Derivatives with antagonistic and inverse agonistic activity are
also found in these series.
Figure 7.
Full agonists
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Antagonist
                                                      RU 33094
Partial inverse agonists
                           RU 33697                                              RU 33356
Full inverse agonists
                              RU 34000                                            RU 34317
Figure 7. The representative Imidazoquinolines and imidazopyrimidines
with diverse intrinsic efficacy
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1.2.3.4. Pyrazoloquinolines
Figure 8.
Partial and weak partial agonists
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Antagonist or weak inverse agonist
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Full inverse agonist
                                                     S-135
Figure 8. The representative pyrazoloquinolines and derivatives with diverse
intrinsic efficacy
1.2.3.5. Cyclopyrolones and derivatives
Figure 9.
Full agonists
                                        Zopiclone                                        Suriclone
Partial agonists
                                        RP 59037                                         DN 2327
Figure 9. The representative cyclopyrolones and derivatives
N
NN
O
S
CH3
N
O
O
O
N
N CH3
N
Cl
N
N
S
S
N
O
O
O
N
N CH3
N
N
Cl
N
O
O
CH3
H3C
N
N
Cl
N
O
O
N
O
O
N
N
Cl
28
1.2.3.6. Triazolopyridazines
CL 218872 was the first BZD receptor ligand to show an affinity for BZD1 receptors
and initiated the characterisation of the BZD1 and BZD2 receptor subtypes. It can
antagonised the muscle relaxant effects of diazepam in mice, suggested that CL 218872
is a partial agonist. GABA ratio values (defined on page 12) for CL 218872 is smaller
than that of zolpidem (full agonist) and greater than flumazenil (antagonist). Similarly,
CL 218872 showed low maximum potentiation of GABA-induced chloride currents in
isolated frog sensory neurones (Haefely et al., 1985; Gardner et al., 1993; Doble and
Martin, 1996). SR 95195 is a derivative of CL 218872, shows inverse agonists
properties with low affinity to BZD receptors (IC50 4 ∼ 8 µM).
Figure 10.
                                      CL 218872                                        SR 95195
Figure 10. The representative triazolopyridazines
1.2.3.7. Imidazopyridines
The imidazopyridines, zolpidem and alpidem, exhibit high affinity for the BZD
receptors. Zolpidem shows selectivity for the BZD1 receptor subtype, and shows strong
agonist efficacy as measured in vitro (e.g. GABA ratio of 3). Alpidem, a close analogue
of zolpidem, also shows selectivity to the BZD1 receptor subtype in the brain but also
has high affinity for peripheral BZD receptors. Behavioural profiles indicate that
alpidem may be a partial agonist.
Figure 11.
                         Zolpidem                                                     Alpidem
Figure 11. The representative imidazopyridines
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1.3. Picrotoxin and TBPS binding site
Picrotoxin is an equimolar mixture of picrotoxinin and picrotin isolated from Anamirta
cocculus and related poisonous plants of the moonseed family (Johnston, 1996a). The
cage convulsants t-butylbicyclophosphorothionate (TBPS) shares, with picrotoxin, the
same unique binding site on GABAARs, where they act to inhibit the amplitude of
neuronal GABA-activated Cl- currents (Bowery et al., 1976; Squires et al., 1983).
Picrotoxin acts noncompetitively to decrease GABA currents (Newland and Cull-Candy,
1992), and is thought to either act at the channel itself or at the site near the Cl- channel
(Barker et al., 1983; Akaike and Oomura, 1984; Akaike et al., 1985; Bormann, 1988).
These binding sites were originally identified by [3H]α-dihydro-picrotoxinin (DHP) or
[35S]TBPS (Olsen, 1982; Squires et al., 1983). Convulsant compounds that bind to the
TBPS binding sites reduce the Cl- conductance directly by hindering the entry of Cl-
across the ion channel (Sieghart, 1992).
Picrotoxin and cage convulsants do not or only partially and allosterically inhibit GABA
receptor binding and do not displace BZD from their high-affinity binding sites, but
allosterically modulated BZD receptor binding (Olsen, 1982; Karobath et al., 1981;
Skerritt and Johnston, 1983; Johnston, 1996a).
GABA, at micromolar concentrations (e.g. 1µM GABA), allosterically inhibited [35S]-
TBPS binding, which could be reversed by GABAAR blockers (Maksay and Simonyi,
1986; Squires and Saederup, 1987; Squires and Saederup, 1993; Squires and Saederup,
1998). In addition to GABA, most other substances known to interact with GABAARs
allosterically modulate these convulsant binding sites labelled by [35S]TBPS. Agents that
mimic or facilitate the effects of GABA on the opening of Cl- channels, such as
barbiturates, etazolate, etomidate and steroids, potently inhibit [35S]TBPS binding by
reducing its binding affinity (as seen by the increase of the IC50 value) (Gee, 1988, Im
and Blakeman, 1991). The binding affinity of [35S]TBPS is enhanced by drugs that
reduce GABA-ergic transmission (Squires et al., 1983; Supavilai and Karobath, 1984;
Gee et al., 1986; Concas et al., 1988). BZD receptor agonists enhance and inverse BZD
receptor agonists reduce [35S]TBPS binding affinity at non-equilibrium conditions,
whereas BZD receptor antagonists are without effect in this binding assay. These effects
are called “TBPS shift”, which is a useful method to predict the efficacy of BZD
receptor ligands. Thus, pure BZD agonists generally give 40% enhancement, whereas
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inverse agonists give 40% inhibition of [35S]TBPS binding (Supavilai and Karobath,
1983; Braestrup et al., 1984; Braestrup and Nielsen, 1986). BZDs agonists can inhibit
the binding of [35S]TBPS only in the presence of micromolar quantities of GABA (Gee,
1988), and stimulate [35S]TBPS binding when GABA was antagonised by bicuculline
(Im and Blakeman, 1991). The latter finding coincides with the observation that BZDs
affect the membrane permeability of Cl- ions only in the presence of GABA.
1.4. Barbiturate binding site
Electrophysiological studies indicate that the sedative hypnotic barbiturates, such as
pentobarbital and secobarbital, enhance the effects of GABA by increasing the average
duration of channel opening (Study and Barker, 1981; Macdonald et al., 1989;
Macdonald and Twyman, 1992; Macdonald and Olsen, 1994). In addition, at high
anaesthetic concentrations (> 50 µM), barbiturates directly increase the time of channel
remains in the opening state, even in the absence of GABA (Bormann, 1988). These
distinct effects of barbiturates indicate the existence of at least two sites of interaction of
barbiturates with the GABAAR (Sieghart, 1995). Recombinant GABAAR studies
indicate different domains within the β-subunits are required for forming a Cl- channel
that can be activated by GABA and pentobarbitone, although, unlike BZDs, the
presence of a γ2 subunit is not necessary (Schofield et al., 1987; Amin and Weiss, 1993;
Horne et al., 1993).
In the binding studies, there are no barbiturates can be radiolabeled with high specific
radioactivity. The affinity for the radiolabeled barbiturates is relatively low. No true
antagonists for barbiturate binding site are available (Ito et al., 1996). However, the
interaction of barbiturates with other binding sites on GABAARs showed that
barbiturates enhanced the binding affinity of [3H]GABA, [3H]muscimol and
[3H]flunitrazepam, and inhibit [35S]TBPS binding, in a manner that correlated with their
rank order of potency as anaesthetics and hypnotics (Olsen, 1982; Squires et al., 1983).
The investigations of the interaction of barbiturates and BZDs showed that barbiturates
appear to stimulate the binding of [3H]BZDs by an effect on their KD (Leeb-Lundberg et
al., 1980). Binding of the inverse agonists (e.g. β-carbolines) is, however, reduced by
barbiturates, and this resulted in the proposal that the extent of this “barbiturate shift”
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may be a measure of efficacy for ligands acting at the BZD site (Wong et al., 1984;
Honore et al., 1984).
1.5. Neurosteroids binding site
Electrophysiological studies showed that alphaxolone selectively enhanced the
inhibitory effects of GABA via GABAARs, which provided a mechanism of  the
anaesthetic action of this compound (Harrison and Simmonds, 1984). A number of
structurally related endogenous steroids, such as progesterone metabolites 5α-pregnan-
3α-ol-20-one and 5β-pregnan-3α-ol-20-one and deoxycorticosterone metabolite 5α-
pregnan-3α, 21-diol-20-one have been shown to mimic this effect and were even more
potent than alphaxolone (Callachan, et al., 1987; Peters et al., 1988; Lambert et al.,
1995; Olsen and Sapp 1995). At low concentrations (30 to 300 nM) these compounds
enhance GABA-stimulated chloride conductance (Majewska, 1992; Kokate et al.,
1994). At high concentrations (> 1µM), these steroids, like barbiturates, produce a
direct opening of the GABAAR associated Cl- channel in the absence of GABA that
could be inhibited by the GABAAR antagonist bicuculline (Callachan et al., 1987;
Majewska, 1992). The activation of GABAARs by steroids increased both the frequency
(BZD-like effect) and duration (barbiturate-like effect) of Cl- channel opening (Peters et
al., 1988; Twyman and Macdonald 1992).
In the binding studies, neurosteroids enhanced the binding of the [3H]muscimol
(GABAAR agonist) both by an increase in binding affinity and an increase in the
number of binding sites (Harrison et al., 1987; Lopez-Colome et al., 1990).
Neurosteroids can also enhance the affinity of the BZD receptor agonist
[3H]flunitrazepam in a picrotoxin-sensitive way and allosterically inhibit binding of
[35S]TBPS to GABAAR (Gee, 1988; Schumacher and McEwen, 1989; Majewska,
1992). Although many of the effects of neurosteroids are similar to those of barbiturates
on GABAARs, the data from pharmacological analyses utilising steroid-barbiturate and
steroid-BZD drug combinations in electrophysiological and radioligand binding
experiments indicated that they appear to interact with different sites on GABAARs
(Gee, 1988; Lambert et al., 1995, 1996). The behavioural effects of neurosteroids acting
on the GABAARs include anxiolytic, anticonvulsant, sedative-hypnotic and anaesthetic
activities both in animals and in humans (Majewska, 1992; Gee et al., 1995; Lambert et
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al., 1995). The doses of neurosteroids required for their anticonvulsant action and the
sedative effect are not identical but close to each other. Thus, the development of steroid
with a more subtle influence on the GABAAR (e.g. pregnanediols) may prove to be a
useful strategy to overcome the sedative properties of the steroids (Lambert et al. 1995).
1.6. Ethanol binding site
Ethanol exhibits a large variety of different effects on the nervous system. It not only
influences membrane fluidity, neuronal electric activity and synaptic transmission, but
also exhibit specific actions on both voltage-gated (Ca2+ and K+ channels) and
transmitter-gated ion channels (e.g. glutamate receptor, GABAAR, 5-hydroxytryptamine
(5-HT) receptor, nicotinic acetylcholine (nAch) receptor and glycine receptor ion
channels) (Deitrich et al., 1989; Morrow, 1995; Crews et al., 1996; Miczek et al., 1997).
Many pharmacological effects of ethanol are similar to those of BZDs and barbiturates,
including anticonvulsant, anxiolytic, ataxic and sedative-hypnotic effects, suggest the
facts that GABAAR may be the target mainly responsible for many of the actions of
ethanol (Crews et al., 1996). At pharmacologically relevant concentrations, ethanol has
been shown to stimulate or potentiate GABAAR-mediated 36Cl- uptake in subcellular
brain preparations from rat cerebral cortex and cultured embryonic neurons, (Suzdak et
al 1986, 1987; Mehta and Ticku, 1988). Electrophysiological studies have confirmed
that the enhancing effect of ethanol on the GABAAR-mediated Cl- conductance depends
on the molecular composition of GABAARs (GABAAR subtypes) appeared in specific
brain regions or cell populations (Givens and Breese, 1990a, b; Aguayo, 1990;
Reynolds and Prasad, 1991; Criswell et al., 1993; 1995). The enhancement of GABAAR
responses induced by ethanol at relatively low concentrations (20 mM), but not at
higher anaesthetic concentrations (50 ∼ 400 mM), is dependent on the presence of the
alternatively spliced variant of the γ2 subunit (γ2L). This subunit contains an extra 8
amino acids ( as compared to the short form γ2S) in the region between the third and
fourth transmembrane domain (TM3 and TM4) (Wafford et al., 1991; Wafford and
Whiting, 1992; Mihic et al., 1994a). Cerebellar granule cells contain recognition sites
for the BZD inverse agonist Ro 15-4513, which can antagonise the effects of ethanol on
some behavioural effects of ethanol in animals (such as the exploration and anxiety) as
the effect of ethanol on GABA-mediated responses (Lister and Nutt, 1988; Ticku and
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Kulkarni, 1988; Lüddens et al., 1990). Receptors containing the α6 subunits, which
confer the sensitivity to the BZD inverse agonist Ro 15-4513, may be responsible for
the action of ethanol in the cerebellar granule cells (Lüddens et al., 1990). In thalamus,
Ro 15-4513 binds with high affinity to the GABAARs consisting of α4 subunits,
suggesting the α4 containing GABAARs could be another target for ethanol  (Wisden et
al., 1991). Chronic ethanol treatment differentially alters the expression of GABAAR
subunit mRNAs in the cerebral cortex and cerebellum. The levels of GABAAR α1
subunit mRNAs are reduced whereas α4 subunit mRNAs are increased by
approximately equal amounts in cerebral cortex. In the cerebellum, decreases in
GABAAR α1 subunit mRNAs and increase in α6 subunit mRNA levels are found. These
changes in mRNA levels suggest alterations in the expression of the corresponding
proteins that could account for the alterations in receptor function and binding that have
been observed (Morrow et al., 1990, 1992; Mhatre and Ticku, 1993; Ticku and Mhatre,
1994; Devaud et al., 1995).
1.7. GABAARs and neurological disease
1.7.1. Epilepsy
The deficit in GABA-ergic inhibitory synaptic transmission might contribute to the
neuronal epileptic activity and the spread of focal seizure activity (Gale, 1992; Olsen et
al., 1992).  Compounds that potentiate the synthesis, synaptic release, postsynaptic
action of GABA show anticonvulsant activity. Actually, many of the antiepileptic drugs
exert their action by enhancing the brain GABA activity (e.g. BZDs, barbiturates,
vigabatrin etc.) (Emilien and Maloteaux, 1998). The modulatory mechanism of BZDs
and barbiturates on the GABAA/BZD receptors has been discussed (see Section 1.2. and
1.4.). Vigabatrin, a synthetic derivative of GABA, increases brain GABA levels by
irreversibly inhibiting GABA-transaminase (the primary presynaptic degradative
enzyme of GABA), thus enhances GABA-ergic transmission decreases seizure activity
(Macdonald and Kelly, 1995; Emilien and Maloteaux, 1998).
The alteration of GABAARs has been observed in animal models as well as in human
with epilepsy. In kindling-induced seizure in rats, a regionally specific alteration of
GABAA/BZD receptor binding has been observed (Titulaer et al., 1994; 1995a, b, c).
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Detected by [3H]muscimol (Titulaer et al., 1994), [3H]flunitrazepam (Titulaer et al.,
1995a), [35S]TBPS binding (Titulaer et al., 1995b) and muscimol-stimulated 36Cl-uptake
experiments (Titulaer et al., 1995c), a significant decrease of receptor binding was
found in hippocampal CA1 area, while a profound increase was observed in fascia
dentata area in the kindled rat hippocampus, which means an increased synaptic
inhibition in the dentate and a loss of GABA-ergic inhibition in the CA1. The alteration
of subunit mRNA of the GABAAR was also regional specific. For example, an increase
of α5 subunit mRNA was found in the dentate gyrus, while significant reduced levels of
α2 and α5 subunit mRNA were seen in the hippocampal CA1, CA2 and CA3 regions in
rat pilocarpine-induced epilepsy model (Rice et al., 1996). In the rat model of absence
seizures induced by γ-hydroxybutyric acid, a marked up-regulation in α1 mRNA and a
corresponding down-regulation in α4 mRNA in thalamic relay nuclei, but not in
hippocampus, was observed 2-4 hours after the onset of seizure (Banerjee et al., 1998).
In the kainic acid-induced seizure model, the impairment of GABA-mediated
neurotransmission was found mainly due to the lasting loss of GABAAR containing
cells, and this loss of GABAARs in the hippocampus may partially be compensated by
increased expression of some GABAAR subunits ( e.g. α1, α2, α4, α5, β1, β2, γ2 and δ)
within the molecular layer of the dentate gyrus and in pyramidal cells (Tsunashima et
al., 1997; Schwarzer et al., 1997). In human epilepsy, the changes of GABA-ergic
inhibition are controversial, the functional GABA-ergic inhibition can be reduced,
normal or slightly enhanced (Mody, 1998).
1.7.2. Angelman Syndrome
So far, the gene of β3 subunit seems to the only one among genes encoding the
GABAAR subunits, associated with a defined genetic disease i.e. the Angelman
syndrome (AS). AS is characterised by severe mental retardation, epilepsy,
hyperactivity, sleep disturbances, motor incoordination and craniofacial abnormalities
(Williams et al., 1995). Approximately 70% of AS cases result from a de novo deletion
of 4 Mb of DNA in maternal chromosome 15q11-q13 (Knoll et al., 1989), which co-
localises the genes coding α5, β3 and γ3 subunits of the GABAARs. A mutant mouse line
which lack all three genes (α5, β3 and γ3) has a lethal cleft palate defect. Those mice,
who do survive show a variable neurological phenotype (e.g. tremor, jerky gait), while
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the mice lacking the α5 and/or γ3 appear phenotypically normal. This indicates that
deletion of the β3 gene alone is responsible for the defects (Nakatsu et al., 1993; Culiat
et al., 1994). The β3 gene knock-out mice do have a epilepsy phenotype and show
marked similarities (e.g. elctroencephalographic abnormalities, seizures, learning and
memory deficits, poor motor skills on a repetitive task, hyperactivity and disturbed rest-
activity cycle) to the clinical feature of AS, indicating that impaired expression of the
β3 gene in humans probably contributes to the overall phenotype of AS (DeLorey et al.,
1998).
1.7.3. Huntington’s disease
Huntington’s disease (HD) is an inherited neurodegenerative disorder characterised by
progressive involuntary choreiform movements, psychopathological changes, and
dementia. The pathogenesis is unknown, therefore there is currently no known cure for
this disease. One neuropathological characteristic of HD is a profound loss of striatal
projection neurons, leading to atrophy of the caudate nucleus and putamen (Quinn and
Schrag, 1998; Walling et al., 1998). In HD chorea, a decrease in GABA and BZD
receptor binding was found in caudate nucleus and putamen, an increase of binding was
seen in lateral and medial pallidum (Möhler and Okada, 1978; Penney and Young,
1982). For both GABA and BZD binding sites, the decreased binding in striatum, and
the increased binding in globus pallidus, superficial frontal cortex and midfrontal cortex
was found due to the changes in the number of receptors rather than in their affinity
(Whitehouse et al., 1985; Trifiletti et al., 1987). [35S]TBPS binding to the postmortem
brain of HD patient was unchanged, but the enhancement of [35S]TBPS binding by
alpidem, flunitrazepam and clozepam was reduced (Lloyd et al., 1991). The loss of
GABAA/BZD receptors was also shown by positron emission tomographic, postmortem
autoradiographic and immunohistochemical studies (Holthoff et al., 1993; Faull et al.,
1993). On animal model of HD (quinolinic acid lesions in striatum), a marked loss of
GABA immunoreactivity and a increase in the density of GABAAR in the substantia
nigra pars reticulata was observed (Nicholson et al., 1995). A reduced anxiety was seen
in HD transgenic mice as tested in the elevated plus-maze tests (File et al., 1998).
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1.7.4. Parkinson’s disease
Parkinson's disease (PD) is a neurodegenerative disorder, in which neurons of various
neuronal systems degenerate, a deficiency of dopamine in the nigrostriatal system is one
of the most notable characteristics (Birtwistle and Baldwin, 1998; Gelb et al., 1999). In
PD, GABA receptor binding, as well as glutamic acid decarboxylase was decreased in
the substantia nigra and caudate nucleus relative to normal controls (Rinne et al., 1984;
Nishino et al., 1988). GABAAR densities were significantly decreased in both the
cortical and subcortical brain regions, which possibly reflects the degeneration of
neurons on which the receptor is localised (Nishino et al., 1988).  Specific binding of
[3H]flunitrazepam to the BZD receptors is reduced (in the lateral segment of the globus
pallidus, Griffiths et al., 1990), unchanged (in caudate and putamen, Griffiths et al.,
1990) or increased (in caudate nucleus, Maloteaux et al., 1988) in PD. GABA can still
enhance the [3H]flunitrazepam binding, indicated that the functional link between
GABA and BZD receptor remained intact in PD (Maloteaux et al., 1988). In
autoradiographic study, a loss of BZD receptors in the mid and caudal portions of the
putamen was noted (Griffiths et al., 1994). Besides the neuronal BZD, the Platelet
peripheral BZD receptors are also found decreased in PD, which implicated the
abnormalities in mitochondrial function (Bonuccelli et al., 1991). Iomazenil is a high
affinity partial inverse agonist of the central BZD receptors. Assay of cellular up-take of
123I labelled ([123I]iomazenil) iomazenil at the moment evaluated as a useful diagnostic
tool for PD (Kawabata et al., 1996; 1997). The correlation between motor disability and
decrease in [123I]iomazenil uptake in the cerebral cortex suggesting that BZD receptors
in the cerebral cortex of patients with PD may be impaired in proportion to the severity
of the disease, thus [123I]iomazenil will be useful for evaluating the pathophysiological
condition in PD (Kawabata et al., 1996; 1997).
1.7.5. Alzheimer’s disease
Alzheimer’s disease (AD) is a degenerative mental disease characterised by progressive
brain deterioration and dementia. It is the most common cause of dementia in the elder
people, affecting approximately 5 to 10% of those over 65 years of age and possibly
50% of those over 85 years old persons. It is characterised pathologically by senile,
neurofibrillary, and neuropil threads from the examination of the brain tissue after the
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patient’s death, with limited information about its aetiology and pathogenesis (Small,
1995; Sloane, 1998; Small, 1998). In addition to the possible involvement of genetic,
immune, oxidative and inflammatory mechanisms, the cholinergic and other
neurotransmitter changes are probably also involved in the process of AD (Small,
1998). For the GABAA/BZD receptors, a general loss of the receptors in different brain
area is evidenced. Thus, receptor density of both GABAA and GABAB receptors in
layers II, III and V of frontal cortex (Chu et al., 1987a), and hippocampus (Chu et al.,
1987b) in AD patients are significantly different with the age matched controls, while
the binding affinity for GABA to these two receptors is remained. Similarly, the number
of BZD receptors in frontal and temporal cortex and hippocampus was also found
significantly reduced in AD (Shimohama et al., 1988; Jansen et al., 1990). The specific
[35S]TBPS binding was significantly reduced in frontal cortex membranes from AD
patients as compared to normal control, but alpidem, flunitrazepam and clonazepam can
still enhance the [35S]TBPS binding in AD implicating the intact linkage between the
BZD sites and the Cl- channels (Lloyd et al., 1991). Immunohistochemical studies
showed that the GABAAR subunits (β2/3) in the hippocampus are well preserved even
until the terminal stages of AD (Mizukami et al., 1997), while a marked decrease in
neuropil immunolabeling (of α1 subunit) within the CA2, CA1 subregions and
prosubiculum are found in severe AD (Mizukami et al., 1998a). Concerning the mRNAs
levels, β2 mRNA is well-preserved, while β3 mRNA was decreased in hippocampus in
the later stage of AD (Mizukami et al., 1998b). The cholinergic deficits plays a key role
in AD dementing process, an increased cholinergic transmission resulting from
available pharmacotherapy is the only approach shown to be efficacious for the
treatment of AD (Small, 1998). The mnemonic function (memory enhancing function)
of cholinergic neurons may be enhanced by treatments that reduce GABA-ergic
inhibition (Smith et al., 1994). Two partial inverse agonists, FG 7142 (see Figure 6 for
chemical structure, Smith et al., 1994) and S-8510 (2-(3-isoxazolyl)-3,6,7,9-
terahydroimidazo[4,5-d]pyrano+++[4,3-b] pyridine monophosphate monodydrate)
(Kawasaki et al., 1996) have been shown to enhance the mnemonic function with little
risk for inducing anxiety or convulsion in rats, and therefore can be used for
development of therapeutic drug for AD.
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1.7.6. Schizophrenia
Apart from hypotheses of genetic, neuroimmunovirological, retroviral infection, birth
and pregnancy complication related aetiology, the dopamine hypotheses, proposing that
the schizophrenia (SPA) results from the excessive activity at dopamine synapses in the
brain, and that neuroleptic drugs may control the symptoms of SPA by antagonising
dopamine at synaptic receptors, is one of the most important hypotheses for
understanding the mechanism of SPA (Carpenter and Buchanan, 1995; Willner, 1997).
Contrary to the theory that dopamine receptor system is thought directly involved in the
pathogenesis of schizophrenia (SPA), the involvement of GABAA/BZD receptors may
have a rather indirect impact. Nevertheless, some general dysfunctions of GABAA/BZD
receptors have been discovered. A significant increase of in vitro GABA and/or BZD
receptor binding activity has been observed on neurons in, e.g. the prefrontal cortex
(Hanada et al., 1987; Benes et al., 1996a), hippocampus (Benes et al., 1996b) and other
brain regions from the post-mortem tissue of SPA  (Kiuchi et al., 1989). This
hyperactivity of GABAARs may be involved in the pathogenesis and some symptoms of
SPA. Both in vitro (Pandey et al., 1997) and in vivo studies (Ball et al., 1998) showed, a
reduced GABAA/BZD receptor binding in SPA patients on medication with neuroleptics
but not the drug free ones. However, the GABAAR subunit genes (α1, α2, α4, α5, α6, β1
and β3), and mRNAs (α1, α2, α5, β1, β2 and γ2) in the prefrontal cortex of SPA were not
significantly changed (Byerley et al., 1995; Akbarian et al., 1995). Contrary to that, a
reduction in relative abundance of γ2S mRNAs and the associated relative increase in γ2L
mRNAs of the GABAAR in prefrontal cortex of SPA were found (Huntsman et al.,
1998). Both GABA site and BZD site agonists may produce SPA-like symptoms, while
the BZD site partial inverse agonists or partial agonist (e.g. bretazenil) being able to
reduce SPA symptoms (Squires and Saederup, 1991; Delini-Stula and Berdah-
Tordjman, 1996).
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Section 2. Molecular biology of GABAARs
2.1. Multiplicity of GABAAR subunits revealed by molecular cloning
The first two cDNA sequences were identified in 1987, referred to as α1 and β1,
encoding synthetic polypeptides containing 456 and 474 amino acids, respectively
(Schofield et al., 1987).  By screening brain cDNA libraries with cDNA probes and
degenerate oligonucleotide probes constructed from sequences conserved between these
subunit of cDNAs, a family of GABAAR subunit cDNAs was subsequently identified
(for review, see Olsen and Tobin, 1990; Vicini, 1991; Wisden and Seeburg, 1992;
Macdonald and Olsen, 1994; Whiting et al., 1995; Dunn et al, 1994; Doble and Martin
1996). To date, a total of 6α, 4β, 4γ, 1δ and 1ε subunits of the GABAAR have been
cloned and sequenced from mammalian brain (Table 3). Some of them (α1, β2, β3, γ1
and γ2) were also found in chicken, including some additional subtype of the β subunits
(β4) and γ subunits (γ4). Another new class subunit of GABAAR (π subunit) has so far
only been cloned from the reproductive tissues of human and rat (Hedblom and
Kirkness, 1997). The amino acid sequence identity within a particular subunit class is
about 70 to 80% while between classes it is around 30 to 40% (Figure 12). The
homology of amino acid sequences (20 ∼ 30%) of GABAAR subunits with the nAch
receptor, the glycine receptor and the 5-HT3 receptor subunits suggest that these
receptors are members of a superfamily of ligand-gated ion channels (Schofield et al.,
1987; Whiting et al., 1995; Barnard et al., 1998; Hevers and Lüddens, 1998; Vafa and
Schofield, 1998).
The electron-microscopic image analysis performed on GABAARs purified from
porcine brain (Nayeem et al., 1994), as well as molecular study performed on
recombinant α1β1 and α1β1γ2 GABAARs expressed in Sf9 cells (Knight et al., 1998)
suggest that the GABAAR channels were formed from five subunits.
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Figure 12.
Figure 12. Dendrogram showing the relevance of amino acid sequences between
GABAAR subunits. All sequences are from the rat, except of β4 (chicken) and ε
(human). The total lengths of the horizontal branch connecting any two sequences
represents the divergence in their amino acid sequence. The scale bar corresponding to
10% sequence divergence (Adopted from Barnard et al., 1998).
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Table 3.  Cloned GABAAR subunits
Subunit Human Rat Bovine Chicken
α1 Schofield et al.,
1989
Lolait et al.,
1989
Schofield et al.,
1987
Bateson et al.,
1991a
α2 Hadingham et al.,
1993a
Seeburg et al.,
1990
Levitan et al.,
1988
α3 Hadingham et al.,
1993a
Malherbe et al.,
1990
Levitan et al.,
1988
α4 Yang et al., 1995 Seeburg et al.,
1990
Ymer et al.,
1989a
α5 Hadingham et al.,
1993a
Pritchett et al.,
1990
α6 Hadingham et al.,
1996
Lüddens et al.,
1990
Lüddens et al.,
1990
β1 Schofield et al.,
1989
Lolait et al.,
1989
Schofield et al.,
1987
β2 Hadingham et al.,
1993b
Ymer et al.,
1989b
Ymer et al.
1989b
Harvey et al.,
1994
β3 Wagstaff et al.,
1991
Ymer et al.,
1989b
Ymer et al.,
1989b
Bateson et al.,
1990
β4 Bateson et al.,
1991b
γ1 Ymer et al., 1990 Ymer et al.,
1990
Ymer et al.,
1990
Glencorse et
al., 1993
γ2 Pritchett et al.,
1989
Shivers et al.,
1989
Whiting et al.,
1990
Glencorse et
al., 1990
γ3 Hadingham et al.,
1995
Knoflach et al.,
1991
γ4 Harvey et al.,
1993
δ AF016917 Shivers et al.,
1989
ε Davies et al.,
1997
π Hedblom and
Kirkness, 1997
Hedblom and
Kirkness, 1997
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2.2. Molecular structure of GABAAR subunits
All subunits of ligand-gated ion channels including the GABAARs have a similar
molecular structure. A single subunit contains: (1) a large extracellular hydrophilic NH2-
terminus with several potential glycosylation sites and a cysteine bridge formed by two
conserved cysteines; (2) four transmembrane domains (TM1-TM4); (3) a variable (in
length and composition) intracellular loop between TM3 and TM4, which contains
possible phosphorylation sites for protein kinase A and C and tyrosine protein kinase;
(4) a short extracellular C-terminus. The second transmembrane domain (TM2) is
thought to be part of the chloride channel core (Figure 13, Olsen and Tobin, 1990;
Tyndale et al., 1995; Hevers and Lüddens, 1998).
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2.3   Alternative splicing forms of GABAAR subunit
The understanding of the heterogeneity of the GABAAR subunit isoforms is extended
by the identification of alternate splice variants, in which additional sequences can be
included or omitted from the mature mRNA species. Within the GABAAR gene family,
alternative splicing have been identified in four subunits, namely α6, β2, β4, γ2 (Whiting
et al., 1995). The splice variant of the α6 subunit has an omission of 10 amino acids
from the N-terminal domain and constitutes 20% of the total α6 population, but it seems
to form non-functional receptors (Korpi et al., 1994). All other three (β2, β4 and γ2)
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variants occur within the putative large cytoplasmic domain that lies between TM3 and
TM4. The two β2 subunit variants differing by the presence (β2L) and absence (β2S) of
17 amino acids have been identified in both chicken and man (Harvey et al., 1994;
McKinley et al., 1995). Similarly, the two γ2 variants arising by inclusion (γ2L) or
omission (γ2S) of an additional exon, giving an additional 8 amino acids have been
found in bovine, human, mouse and chicken brain (Whiting et al., 1990; Kofuji et al.,
1991; Glencorse et al, 1992). The γ2L subunit have been suggested to be necessary for
the ethanol potentiation of GABAARs (see Section 1.6.). The splice variants of β4
subunit (β4’) with a extra four amino acids has been demonstrated only in chicken
(Bateson et al., 1991b).
2.4  Chromosome assignment of GABAAR subunit genes
The genes coding GABAAR subunits have been assigned to individual chromosomes
(Table 4).
Table 4. Chromosome assignment of GABAAR subunit genes
GABAAR
Subunit gene
Chromosome
Assignment
GABAAR
Subunit gene
Chromosome
Assignment
Human Mouse
α1, α6, β2, γ2 5q32-q33 α5, β3, γ3 7
α2, α4, β1, γ1 4p13-q11 α2, β1 5
α5, β3, γ3 15q11-q13 ρ1, ρ2 4
α3, β4, ε Xq28 α1 11
ρ1, ρ2 6q14-q21 α3 X
δ 1p
Data are collected from different papers (Tyndale et al., 1995; Rabow et al., 1995;
Whiting et al., 1995; McKernan and Whiting 1996; Doble and Martin, 1996; Levin et
al., 1996; Wilke et al., 1997).
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2.5  Pharmacological role of GABAAR subunits
Expression of various combinations of recombinant subunit subtypes in oocytes or
cultured mammalian cell lines has suggested that each of the subunit classes serve
particular roles in defining the functionality of the assembled receptors. The role of
GABAAR subunits has been most well characterised in pharmacological studies of
BZDs. The binding profiles of BZD receptor ligands to the recombinant GABAAR
subtypes expressed in various cell lines are similar to that found in native GABAAR
subtypes (Table 5, Möhler et al., 1997).
2.5.1  α subunit class
The α subunit class is the largest, comprising six members, and it is believed that they
specify the heterogeneity of the BZD binding site (Lüddens et al., 1995; Dunn et al.,
1994). The described BZD1 receptor (see Section 1.2.1.2.) has been shown to consist
primarily of receptors containing an α1 subunit (Pritchett et al., 1989). The subunit
combination α1β2γ2 is the major GABAAR subtype in the brain, which amounts to at
least 60% of the BZD-sensitive GABAARs, as demonstrated by immunoprecipitation
and immunohistochemical localisation (see Section 2.6.) of the three subunits in the
same neurons (Wisden et al., 1992; Ruano et al., 1994; Fritschy and Möhler, 1995;
Möhler et al., 1997). Expressed in transfected cells or Xenopus oocytes, receptors of
α1βγ2 combination showed high affinity for compounds such as CL 218872 and
zolpidem both in biochemical and functional studies (Pritchett et al., 1989; Wafford et
al., 1992; Hadingham et al., 1993a). Receptors containing the α2 and α3 subunits,
represent about 25% of the BZD-sensitive GABAARs and are most abundant in regions
where the α1 subunit is absent or expressed at low levels (Marksitzer et al., 1993; Benke
et al., 1994; Fritschy and Möhler, 1995; Möhler et al., 1997). The subunits combinations
α2βγ2 and α3βγ2 have lower affinity for CL 218872 and zolpidem, are corresponding to
the described BZD2 receptors (see Section 1.2.1.2., Hadingham et al., 1993 a, b). The
α5 subunit containing recombinants (e.g. α5βγ2) also exhibited a BZD2 phenotype but
with a very low affinity for zolpidem, and having some 10-fold selectivity for Ro 15-
4513 over all other receptor subtypes (Pritchett and Seeburg, 1990; Hadingham et al.,
1993 a). α4 and α6 subunit containing receptors have high affinity for the compound Ro
15-4513 and bretazenil and very low affinity for classical BZDs such as diazepam and
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flunitrazepam (Lüddens et al., 1990; Wisden et al., 1991). These receptors localised
primarily in cerebellar granule cells (α6 containing receptors) and thalamus (α4
receptors) are termed “diazepam-insensitive” receptors (Malminiemi and Korpi, 1989;
Lüddens et al., 1990, 1995; Wisden et al., 1992; Laurie et al., 1992). Using site-directed
mutagenesis, the mutant of Glu225 to Gly on the α3 subunit (glycine is the equivalent
residue of α3 with Glu225 in the α1 subunit) confers a BZD1 pharmacological
properties (Pritchett and Seeburg, 1991). The α1, α2, α3 and α5 subunits have a histidine
at position 101, whereas the α4 and α6 subunits have an arginine, the mutant by
substitution of arginine for histidine in α6 subunits confers high-affinity binding of
diazepam (Wieland et al., 1992). This histidine in the α1, α2, α3 and α5 appears to be a
key residue for the action of clinically used BZD ligands (see Section 2.8.2.1.; Wieland
et al., 1992; Kleingoor et al., 1993).
Table 5. Binding profiles of BZD site ligands to the native GABAAR subtypes
KI (µM), [3H]flumazenil binding
Receptor population immunoprecipitated by subunit-specific antisera
α1β2γ2 α2β3γ2 α3β3γ2 α4βxγ2 α5 γ1 γ3 δ
Flumazenil 0.6* 1.2* 1.1* 130 0.6* + 1.1* 0.5*
Flunitrazepam 7 7 8 + 3 38* 854 2
Diazepam 20 25 20 + 20 ND ND 5
Ro 15-4513 ND ND ND 16* 1 + 6.9 0.4
βCCM 2 6 7 ND 3 1550 11 0.2
Zolpidem 12 100 83 + 30 + + 43
CL 218872 195 960 670 + 280 400 227 400
KI was determined for receptor populations immunoprecipitated from whole rat brain
with the respective α, β, γ or δ subunit specific antiserum. +: KI > 10,000 µM; *: values
represent KD from Scatchard plot. ND: not determined (from Möhler et al., 1997).
2.5.2  β subunit class
The particular β subunit isoform appears to have little influence on the characteristics of
the BZD recognition site (Pritchett et al., 1989; Wisden and Seeburg, 1992; Hadingham
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et al., 1993b). However, it was demonstrated that the β1, β2 or β3 subunits differentially
influenced the [35S]TBPS binding of recombinant receptors and its modulation by BZDs
(Lüddens et al., 1994). The action of the anticonvulsant compound loreclezole was
demonstrated depended on the type of the β subunit present in recombinant receptors. A
more than 300-fold higher affinity for receptors containing β2 or β3 subunits over those
containing β1 subunits was observed (Wingrove et al., 1994). A single amino acid, β2
Asn289 (β3 Asn290), located at the carboxyl-terminal end of the putative channel-lining
domain TM2, confers the sensitivity to the modulatory effects of loreclezole (Wingrove
et al., 1994).
2.5.3  γ subunit class
The most important γ subunit is γ2 that was found necessary to form a fully functional
GABAAR with a high-affinity BZD binding site (Pritchett et al., 1989). Among the two
splicing forms (see Section 2.3., γ2S and γ2L), most of the studies so far performed have
used the short form of the γ2 subunit (γ2S) for the construction of recombinant receptors
(Sieghart, 1995). γ subunits (γ1-3) when expressed together with α and β subunits, confer
BZD recognition properties on the expressed receptors, but receptors containing γ1 and
γ3 exhibit pharmacological differences from those containing a γ2 subunit with regard to
both BZD affinity and efficacy (Pritchett et al., 1989; Ymer et al., 1990; Knoflach et al.,
1991; Puia et al., 1991; Wafford et al., 1993; Herb et al., 1992 Lüddens et al., 1994).
Combining with an α and a β subunit, receptors containing the γ1 subunit have a marked
decrease in affinity for the antagonist flumazenil and the inverse agonist DMCM as
compared to the receptors containing γ2 subunit (Ymer et al., 1990; Wafford et al.,
1993). In contrast, α1β2γ3 shows a marked decrease in BZD agonist affinity (but not the
affinity to BZD antagonists or inverse agonists) as compared to that of the α1β2γ2
(Wafford et al., 1993). Recombinant receptor combinations containing a γ2 subunit
confer insensitivity to Zn2+ (Draguhn et al., 1990; Smart et al., 1991). Both the α and γ
subunits are necessary for a receptor to exhibit sensitivity to BZDs, and it have been
proposed that the BZD binding domain is formed with contributions from both subunits
(see Section 2.8.; Stephenson et al., 1990; McKernan et al., 1995; Wingrove et al.,
1997).
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2.5.4  δ subunit class
This subunit (455 AA) form homo-oligomers in human embryonic kidney 293
(HEK293) cells that display GABA-gated channels with small currents that are sensitive
to picrotoxin, bicuculline and pentobarbital (Shivers et al., 1989). δ subunit was found
co-localised with α1, α4 and β2 mRNAs in large number of regions (principally thalamic
nuclei), with α1, α6 and β2/3 in the cerebellum granule cells, to possibly form α1α4βδ
and α1α6βδ containing receptors which have high affinity to muscimol but lack BZD
binding sites (Wisden et al., 1992). The subunit combinations α1β2/3γ2δ and α2α5δ may
also exist in some brain regions (Fritschy and Möhler, 1995). Co-expressed with α1 and
β1, the formed subunit combination α1β1δ has a slowed rate of desensitisation and is
potently blocked by zinc and is insensitive to diazepam (Saxena and Macdonald, 1994).
In vivo, the receptors containing δ subunit as detected by immunoprecipitation,
comprise a novel population of GABAARs which do not bind BZDs but have a 5-fold
higher affinity for muscimol as compared with the receptors containing γ2 subunit
(Quirk et al., 1995). Transfected in HEK293 cells, the presence of the δ subunit inhibits
GABAAR modulation but not the direct activation by neurosteroids (3α, 21-dihydroxy-
5α-pregnan-20-1 and Pregnenolone sulphate) (Zhu et al., 1996a). The δ subunit mRNA
expression in cerebellum was up-regulated in pentobarbital-tolerant mice and was
down-regulated in pentobarbital-withdrawn mice (Lin and Wang, 1996), inhibited by
the inactivation of α6 subunit gene in cerebellar granule cells (Jones et al., 1997), and
selectively modulated by KCl-induced depolarisation, a condition that mimics the
effects of neuronal activity through a pathway involving calcium entry and activation of
a Ca2+/calmodulin-dependent protein kinases in cultured rat cerebellar granule neurons
(Gault and Siegel, 1997).
2.5.5   ε subunit class
This polypeptide is 506 amino acids in length and exhibits its greatest amino acid
sequence identity with the γ3 subunit within the GABAAR (Whiting et al., 1997). It can
assemble with α and β subunits and confer an insensitivity to the potentiating effects of
intravenous anaesthetic agents (Davies et al., 1997). The α1β1ε GABAARs, like α1β1γ2S
receptors, are modulated by pentobarbital and the steroid 5α-pregnan-3α-ol-20-1 but,
50
unlike α1β1γ2S receptors, are insensitive to flunitrazepam. Additionally, α1β1ε receptors
exhibit rapid desensitisation kinetics, as compared with α1β1γ2S (Whiting et al., 1997).
In situ hybridisation and immunocytochemistry reveal a pattern of expression of ε
subunit in the brain restricted primarily to the hypothalamus (Whiting et al., 1997).
Clustered together with the α3 and β4, the gene coding human GABAAR subunit ε has
been assigned to chromosome band Xq28, located in the candidate regions of two
different neurological diseases: early onset Parkinsonism and X-linked mental
retardation (Wilke et al., 1997).
2.5.6    π subunit class
This subunit (440 AA) displays 30-40% amino acid identity with other subunit classes
(e.g. α, β, γ) within the GABAAR subunit family and represents a distinct subunit class.
It has been identified in human and rat tissues (Hedblom and Kirkness, 1997).
Transcripts of the π subunit were detected in several human tissues and were
particularly abundant in the uterus. Transient expressing π subunit cDNA alone,
HEK293 cells did not express binding sites for the GABAAR ligands, [3H]muscimol or
[35S]TBPS (Hedblom and Kirkness, 1997). These cells also failed to elicit chloride
currents in response to 100 µM GABA or 100 µM glycine. When cells were
cotransfected with cDNA encoding the π subunit, and either an α1 or a β1 subunit, there
was also a failure to detect expression of any ligand binding activities. The transfection
of cells with a combination of α, β and π subunits resulted in the expression of both
[3H]muscimol and [35S]TBPS binding sites, but not the binding sites for [3H]Ro 15-
1788 or [3H]flunitrazepam. The cells cotransfected with β3/π showed a significant
reduced sensitivity (factor 9) to the endogenous steroid, pregnolone, as compared to the
β3 homomeric receptors (Hedblom and Kirkness, 1997).
2.6    GABAAR subtypes in the brain
The multiplicity of GABAAR subunit isoforms suggests that a large number of receptor
subtypes may exist. Without restriction on subunit assembly, a theoretical maximum of
155 (759375) different receptor subtypes would be possible for the 15 subunit isoforms
found in human brain. However, the number of theoretical possibilities of GABAAR
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subtypes in brain is considerably reduced (ca. 10,000) concerning the fact that at least
one α subunit, one β subunit and one γ subunit are required to form a fully functional
receptor (Pritchett et al., 1989). The evidence currently available suggests that there are
perhaps only 10 to 15 (Doble and Martin, 1996) or less (McKernan and Whiting, 1996)
major subtypes occurring in vivo (Table 6).
Two approaches mainly contributed to this conclusion. The first is tracing sites of gene
expression using in situ hybridisation. Because of overlapping co-localisation, certain
subunit combinations are considered as likely to represent native receptor isoforms (e.g.
Wisden et al., 1992). The second is mapping the site of protein expression using
subunit-specific antibodies (immunocytochemistry, e.g. Fritschy and Möhler, 1995).
Table 6.  Distribution of the major GABAAR subtype in the rat brain∗
GABAAR
subtype
Relative
abundance
in rat brain (%)
Location and putative function
α1β2γ2 43 Present in most brain areas. Localised to interneurons
in hippocampus and cortex and cerebral Purkinje
cells
α2β2/3γ2 18 Present on spinal cord motoneurones and
hippocampal pyramidal cells
α3βnγ2/3 17 Present on cholinergic and monoaminergic neurones
where they regulate Ach and monoamine turnover
α2βnγ1 8 Present on Bergmann glia, nuclei of the limbic
systems and in pancreas
α5β3γ2/3 4 Predominantly present on hippocampal pyramidal
cells
α6βγ2 2 Present on cerebellar granule cells
α6βδ 2 Present on cerebellar granule cells
α4βδ 3 Present in thalamus and hippocampal dentate gyrus
Other
minor
subtypes
3 Present throughout brain
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∗ Other minor subtypes include α1α6βγ2, α1α3βγ2, α2α3βγ2 and α5βγ2δ subtypes and are
represented together as a small population (Adopted from McKernan and Whiting,
1996).
According to these two approaches, the α1β2γ2 subunit combination represent the most
abundant GABAAR subtype in the brain (Laurie et al., 1992; Wisden et al., 1992; Benke
et al., 1991, 1994; Fritschy et al., 1992; Fritschy and Möhler, 1995; Möhler et al., 1997).
It amounts almost 50% of all GABAAR population in the brain (McKernan and
Whiting, 1996). It is not only the main component in GABA-ergic signal transduction,
but also mediates the basic pharmacological spectrum of the classical BZD receptor
ligands (see Section 2.5.1., Möhler et al., 1997). Concerning identified neurons, α1β2γ2
receptors are expressed in numerous populations of GABA-ergic neurons, particularly
the GABA-ergic neurons in the cerebellum, brainstem reticular formation, pallidum,
substantia nigra and basal forebrain, as well as interneurons in cerebral cortex and
hippocampus (Möhler et al., 1997).
The second possibly most abundant subtypes of native GABAARs are α2β3γ2 and
α3β3γ2, which account to approximately 35% of the total GABAAR population
(McKernan and Whiting, 1996). The α2β3γ2 subtype are most abundant in regions as
striatum, hippocampus (e.g. hippocampal pyramidal cells) and olfactory bulb, while
α3β3γ2 subtype are abundant in lateral septum, reticular nucleus of the thalamus and
several brainstem nuclei (Fritschy and Möhler, 1995; Möhler et al., 1997).
The α5β2/3γ2 subtype represents one of the numerous minor GABAAR subtypes in the
brain (Möhler et al., 1997). They are relatively highly expressed in the hippocampus, in
which they constitute approximately 20% of the GABAAR population (McKernan et al.,
1991). In addition, α5β2/3γ2 receptors are also found in olfactory bulb, hypothalamus and
trigeminal sensory nucleus (Fritschy and Möhler, 1995). Based on mRNA and protein
colocalisation further subunit combinations have been suggested such as α6βγ2, α6βδ in
the cerebellar granule cells, α4βδ in thalamus and hippocampal dentate gyrus, and
α1α4βδ, α1α6βδ, α1α6βγ2 or α1α3β2/3γ2 etc. (Wisden et al., 1992; De Blas, 1996;
Fritschy et al., 1992; Laurie et al., 1992; Fritschy and Möhler, 1995; Jechlinger et al.,
1998).
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2.7.    Functional expression of recombinant GABAARs
There are several expression systems for the investigation of recombinant GABAARs.
One rapid and simple model is made by directly injection of mRNA encoding for
GABAAR subunits into Xenopus oocytes to elicit the biosynthesis of these receptors that
can be investigated by electrophysiological techniques (Levitan et al., 1988; Sigel et al.,
1990). Other expression systems employing the transfection of the  cDNAs coding
different GABAAR subunits into mammalian cells (such as HEK293 cells, Chinese
hamster ovary cells and mouse fibroblasts etc.) and insect cells (e.g. Sf9 cells) that can
be investigated by electrophysiological techniques as well as binding studies (Verdoorn
et al., 1990; Knoflach et al., 1992; Porter et al., 1992; Horne et al., 1993; Pregenzer et
al., 1993; Hartnett et al., 1996; Knight et al., 1998).
The expression efficiency of recombinant receptors in Sf9 insect cell system seems
better than other systems (Sieghart, 1995). A recent study suggested that the Sf9
expression system reproduces the pharmacological properties of native receptors
expressed in the brain (functional GABAARs with respect to both GABA and BZD
binding pharmacology) and allows reproducible construction of receptors of known
composition by an ordered assembly process (Hartnett et al., 1996). The high level of
expression and the ease of co-expression of selected subunit combinations appears to
make the Sf9/baculovirus an ideal system for the study of receptor assembly, subunit
stoichiometry of the receptor complexes, as well as in drug screening studies (Hartnett
et al., 1996; Ai et al., 1997a, c; Knight et al., 1998).
Using the expression systems mentioned above, receptors consisting of a single, two,
three or more subunits of GABAARs have been investigated.
Except of the recently described ε and π subunits, α, β, γ and δ subunits can assemble
into functional homo-oligomeric channels. However, compared to most dual or triple
subunit combinations, the homo-oligomeric channels generally have a lower efficiency
of expression and give rise to smaller currents activated by GABA (Sigel et al., 1990;
Verdoorn et al., 1990; Davies et al., 1997). Since these homo-oligomeric Cl- channels
can be activated by rather high concentrations of GABA, stimulated by barbiturates or
steroids but not BZDs, inhibited by bicuculline and picrotoxinin, the binding sites for
GABA, picrotoxinin, barbiturate and steroid may be present on each of these subunits,
or formed on assembly of these subunits (Pritchett et al., 1989; Shivers et al., 1989;
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Verdoorn et al., 1990; Puia et al., 1990; Atkinson et al., 1992; Joyce et al., 1993;
Sieghart, 1995; Krishek et al., 1996).
As compared to the homo-oligomeric channels, the co-expression of two different
subunits (e.g. α1β2) of GABAARs can form Cl- channels with higher efficiency for
GABA activation (Sigel et al., 1990; Knoflach et al., 1992). There are apparently some
differences in the expression efficiency of dual subunit combinations. For example,
combinations as α1β1 or α1β2 are found consistently expressed in various expressing
systems (Verdoorn et al., 1990; Draguhn et al., 1990; Angelotti et al., 1993). Other
subunit combinations appears to be expressed less efficiently, e.g. the α5β3 (Burgard et
al., 1996) or the α6β3 isoform (Saxena and Macdonald, 1996). The β2γ2 isoform is
reported to show only small Cl- currents (Sigel et al., 1990; Verdoorn et al., 1990;
Draguhn et al., 1990), whereas the β1γ2S or β3γ2L isoforms failed to assemble into
functional channels (Sigel et al., 1990; Angelotti and Macdonald, 1993; Burgard et al.,
1996). The binary combinations of ε subunit (e.g. αε or βε) are non-functional (Davies
et al., 1997). Data summarised by Sieghart indicated that the recombinant GABAARs
consisting α and β subunits are activated by GABA and inhibited by bicuculline and
picrotoxin, and further modulated by barbiturates, steroids, propofol, chlormethiazole,
inhalation anaesthetics and Zn2+, but not modulated by BZDs, La3+  or Ro 5-4864
(Sieghart, 1995). In contrast to receptors consisting of αβ, the BZD binding sites (but
not Zn2+) were found present on recombinant receptors containing αγ or βγ subunit
combinations (Puia et al., 1989; Im et al., 1993; Slany et al., 1994, 1995), which is
consistent with the results from molecular biology that the binding domain for BZD
ligands are located at the α/γ subunit interface (see Section 2.8.2.).
A cellular explanation for the different expression of certain isoforms is reported that
some murine subunits and subunit combinations, including homo-oligomeric α1, β2 and
binary α1γ2L, β2γ2L, are retained in the endoplasmatic reticulum of oocytes and HEK293
cells, and only α1β2, α1β2γ2L could produce functional surface expression (Connolly et
al., 1996). These results suggest that receptor assembly occur by defined pathways,
which may serve to limit the diversity of GABAARs that exist on the surface of neurons
(Connolly et al., 1996).
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Recombinant receptors containing ternary combination as αβγ, αβδ or αβε can
consistently form functional channels and most closely resemble GABAARs found in
the brain (McKernan and Whiting, 1996; Hevers and Lüddens, 1998). The influences of
different subunit isoforms on the pharmacology of the different receptor combinations
have been discussed in Section 2.5.
2.8   Mutational analysis of ligand binding domains in the GABAARs
The molecular cloning of the subunits of the GABAARs provides the opportunity to
evaluate the function of the individual amino acids within the subunit sequence, which
are responsible for the binding and interaction with corresponding ligands. Mutational
analysis studies have revealed some of the functional domains for the recognition of
GABA, BZDs within the GABAARs (Figure 14, Smith and Olsen, 1995; Davies et al.,
1996; Doble and Martin, 1996; Sigel and Buhr, 1997; Hevers and Lüddens, 1998; Vafa
and Schofield 1998).
2.8.1   GABA binding sites
Mutation studies indicate the GABA binding sites are determined by both the α and the
β subunits, and the GABA binding sites may be located at the α-β interface of the
GABAARs (Figure 14., Olsen and Tobin 1990; Macdonald and Olsen, 1994; Mihic et
al., 1995). A Point mutation in the rat α1 subunit at phenylalanine (Phe)64
(phenylalanine to leucine) in the putative N-terminal extracellular domain produced a
marked decrease in agonist and antagonist affinities when co-expressed with β2 and γ2
subunits (Sigel et al., 1992). In our laboratory, the amino acid Ile at position 121 on the
human α1 subunit (homologous to rat α1Ile120) was found to affect the agonist
sensitivity (Westh-Hansen et al., 1997). When coexpressed with β2γ2 in the
baculovirus/Sf9 in sect cell system, the mutation of α1Ile121Val produced receptors
with ca. 30-fold lower affinity to the agonists GABA and muscimol in the antagonist
[3H]SR 95531 binding. Electrophysiological measurements of GABA induced whole-
cell Cl- currents showed a 10-fold decrease in GABAAR sensitivity produced by this
mutation (Westh-Hansen et al., 1997).
Mutational analysis of the β subunit has provided some evidence for the involvement of
tyrosine and threonine residues in GABA recognition. Using rat clones of α1, β2 and γ2
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subunits expressed in Xenopus oocytes, Amin and Weiss identified two domains in the
β subunit which appear to be crucial for the activation of the receptor by GABA (Amin
and Weiss, 1993).  The two domains (Tyr157-Thr160 and Thr202-Tyr205), situated
between the disulphide loop and TM1. Mutation of Tyr157 or Tyr205 to Phe, or Thr160
or Thr202 to Ser in the β2 subunit significantly reduced binding affinity (20- to 50-fold)
for both agonists and antagonists at the GABA binding site. Mutations in the
corresponding residues in α and γ subunits or other residues in these two domains had
little or no effect. The mutated receptors could still be activated by pentobarbital (Amin
and Weiss, 1993).
The structural and sequence similarities shared by the members of the ligand-gated ion
channels family of receptors suggest that functional domains of the receptor may also be
located in homologous portions of different receptor subunits (Vafa and Schofield,
1998). Within the nAch receptor, four discontinuous sequence loops have been shown
to constitute the ligand-binding domains (Changeux, 1995; Hucho et al., 1996). Since
these four extracellular domains appear to be conserved across all of the ligand-gated
ion channel receptors as homologous domains, the four-loop  (Loop A, B, C and D)
model of ligand binding domains has been proposed to apply for all members of the
ligand-gated ion channel receptor superfamily (Changeux, 1995; Hucho et al., 1996;
Vafa and Schofield, 1998). For example, the GABAAR β subunit residues Tyr157 and
Thr160 are homologous to the loop B domain residues of the nAch receptor (Trp149,
Tyr151) and the glycine receptor (Phe159, Tyr161), Whereas the residues Thr202 and
Tyr205 are homologous to the loop C ligand-binding domain to residues of nAch
receptor (Tyr190, Cys192 and Cys193) and the glycine receptor Lys200, Tyr202 and
Thr204), respectively (Vafa and Schofield, 1998).
2.8.2BZD binding sites
Pharmacological analyses of GABAAR subtypes have suggested that both the α and γ
subunits, but not the β subunit, contribute to the BZD binding site. Like the agonist
binding site, the BZD site are believed to be located at the α/γ subunit interface (Figure
14., Smith and Olsen, 1995; Sigel and Buhr, 1997).  Several important amino acid
residues on the different α subunit as well as the γ2 subunit involved in the binding of
BZD ligands have been identified.
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2.8.2.1 The important residues on the α subunits
The histidine residue in rat α1 subunit (His101) was shown to confer diazepam-sensitive
BZD binding (Wieland et al, 1992). While mutation of this residue to Arg (a
homologous residue in α4 and α6 subunit) produced a subunit which was insensitive to
BZD agonists diazepam, zolpidem and CL 218872 when co-expressed with β2 and γ2
subunits in HEK293 cells. There was also a 200-fold decrease in the affinity of the
receptor for the BZD antagonist, Ro 15-1788, while the binding affinity for [3H]Ro 15-
4513 was retained. The receptors containing the reverse mutation of α6 subunit (Arg101
to His101) gained sensitivity to BZD agonists (Wieland et al., 1992). Replacement of
the Tyr159 of the α1 subunit by Ser resulted in the loss of [3H]Ro 15-1788 binding
(Amin et al., 1997). Co-expressed with β2 and γ2 in HEK293 cells, receptors containing
the mutant of α1 (Tyr209 to Gln) showed approximately 40-fold decrease in affinity for
[3H]Ro 15-1788 and diazepam, while the α1 (Tyr209 to Phe) mutant containing
receptors showed a small to moderate decrease in affinity for [3H]Ro 15-1788,
diazepam, DMCM and CL 218872 (Buhr et al., 1997b). The α1Tyr209Gln mutation
confers loss of any detectable binding affinity for [3H]Ro 15-1788 and
[3H]flunitrazepam, while the affinity to agonist [3H]muscimol remain unchanged (Buhr
et al., 1997b). Another two mutations on the α1 subunit (Tyr161Ala and Thr206Ala)
increase the sensitivity to both diazepam, CL 218872 and zolpidem (Buhr et al., 1996;
1997b).
In the rat α3 subunit, if Glu225 is mutated to a Gly (the homologous residue to α1),
there is a more than tenfold increase in binding affinities for zolpidem and Cl218872
(Pritchett and Seeburg, 1991).
When four residues in the rat α6 subunit (Arg100, Pro161, Glu199 and Ile121) were
substituted with the corresponding residues present in the α1 subunit (His101, Thr162,
Gly200 and Val212), the mutant receptors gained more sensitivity to BZD agonist
(Wieland and Lüddens, 1994).
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Figure 14.
Figure 14. The binding domains for GABA and the BZD ligands identified on
different subunits of the GABAA/BZD receptors. The numbers indicate amino acid
residues of the corresponding mature rat subunit isoform. The identical or directly
homologous amino acid residues of GABA and BZD binding sites are shown in the
same colour. A, agonist (GABA) binding site; M, modulatory site for BZD ligands.
(Modified from Sigel and Buhr, 1997.
2.8.2.2. The important residues on the γ2 subunit
Expression of recombinant receptors indicates that a γ subunit is absolutely required for
the formation of a BZD binding site (Pritchett et al., 1989; Sigel et al., 1990). Upon
deletion of γ2 from mice the [3H]Ro 15-1788 binding site nearly disappears, confirming
the essential role of γ subunits (Günther et al., 1995).Two amino acid residues on the γ2
subunit (Phe77 and Met130) showed pronounced influences on  the receptor binding
pharmacology (Buhr et al., 1996; Buhr and Sigel, 1997; Buhr et al., 1997a; Wingrove et
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al., 1997). Depending on the amino acid side-chain present at position 77 of the γ2
subunit, BZD site ligands specificity and affinity were differentially affected. The
Phe77Tyr substitution increased the affinity of the receptors to zolpidem and CL
218872 had little effect on Ro 15-1788 binding, but reduced the affinity of the receptors
to diazepam with a factor of 230 (Buhr et al., 1997a),. In contrast, the Phe77Ile mutation
resulted in little change in the diazepam affinity, whereas there was a strongly reduced
affinity for zolpidem and DMCM with a factor of 300 and 900, respectively (Buhr et al.,
1997a). This effect of Phe77Ile mutation is in agree with the results of Wingrove et al.
(Wingrove et al., 1997).
γ2Met130 was required for high affinity binding of flunitrazepam, clonazepam and
triazolam but not Ro 15-1788, Cl 21 8872 or βCCM (β-carboline-3-carboxylic acid
methyl ester) and did not affect BZD efficacy (Wingrove et al., 1997). Substitution of
Met130 to Leu of γ2 subunit resulted in a 51-fold reduction in zolpidem affinity whereas
the affinity to [3H]Ro 15-1788 remained unchanged (Buhr and Sigel, 1997). The affinity
for diazepam was only decreased by about 2-fold, and for CL 218872 increased 9-fold
(Buhr and Sigel, 1997).
Another amino acid in the γ2 subunit that has also been shown to directly affect the
efficacy of BZD compounds is Thr142, which when mutated to serine increased the
efficacy of BZD ligands, changing Ro 15-1788 and Ro 15-4513 to agonists, while BZD
affinity remained (Mihic et al., 1994b).
2.8.3. Homology of the domains between the BZD site and the agonist site
Although no homologous region on other subunit isoforms involved in GABA
interaction has been described for residue α1H101, it is equivalent to the α subunit
residue Tyr93 of the nicotinic acetylcholine receptor, which was shown to be involved
in the binding of agonists and the competitive antagonists (Galzi and Changeux, 1994).
In addition, in the model proposed by Smith and Olsen, two α subunit regions,
beginning at Thr60 and Thr95 are proposed likely involved in the GABA and BZD
binding sites, respectively. The common sequence ThrXAspXThrThr (X is variable
amino acid) and the conservation of both regions in all α subunits, suggest that part of
the BZD binding site on the GABAAR α subunit may be a modified form of an agonist
site (Smith and Olsen, 1995). The following residues, which are important for BZD
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binding, are identical or homologous to the residues important for the GABA binding,
γPhe77 to αPhe64, αTyr159 to βTyr157, αThr206 to βThr202 and αPhe209 to
βPhe205. αGly200, αVal211 and γMet130 of the BZD binding site are located in
homologous regions to βTyr205 and αIle120 of the GABA binding site, respectively.
Based on the available data, a hypothetical model of the binding pocket for agonist and
modulatory BZDs is proposed (Figure 14; Sigel and Buhr, 1997).
2.8. Subunits stoichiometry and arrangement of GABAARs
The subunit stoichiometries for recombinant α3β2γ2 receptors have been proposed as 2α,
1β, and 2γ; 2α, 2β and 1γ or 1α, 2β and 2γ, of which the 2:1:2 (α:β:γ) composition may
be favoured (Backus et al., 1993). Other studies, in which either only one β subunit is
present (Benke et al., 1994) or both the γ2 and γ3 subunits can be co-assembled in native
GABAARs (Benke et al., 1996), seem to support this finding. Recently, two different
studies reach the same conclusion that the recombinant GABAAR is a pentamer
composed of two α, two β and one γ subunit (Chang et al., 1996; Tretter et al., 1997).
The first study probed the stoichiometry of the GABAAR by site-directed mutagenesis
of a conserved leucine (to serine) in the putative second membrane-spanning domain of
the rat α1 (αLeu263Ser), β2 (βLeu259Ser) and γ2 (γLeu274Ser) subunit isoform (Chang
et al., 1996). Co-expression of wild type and mutant subunits of each class (e.g. α and
αLeu263Ser), along with their wild type counterparts (e.g. β and γ), in Xenopus oocytes
resulted in mixed populations of receptors with different GABA sensitivities. The
apparent number of incorporated subunits for each class (α, β and γ) could then be
determined from the number of fractions comprising the GABA dose-response
relationship curves. For example, when a mutated α (αm) co-expressed with wild type
α, β and γ in the same oocyte, the resulting dose-response relationship had three
fractions, and two of the EC50s (the concentration of GABA yielding a current half of
the maximum) deduced from these three fractions are corresponding to the EC50s
deduced from composition of αβγ and αmβγ, respectively. The third EC50 (deduced
from the intermediate fraction) indicated that the GABA receptor must contain more
than one α subunits (αmαβγ combination)  (Chang et al., 1996). In the other study, the
ratio of subunits in recombinant α1β3γ2 receptors was determined in Western blots from
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the relative signal intensities of antibodies directed against the N terminus or the
cytoplasmic loop of different subunits. The relative reactivity of these antibodies had
been determined with GABAAR subunit chimeras composed of the N-terminal domain
of one and the remaining part of the other subunit (Tretter et al., 1997). In the same
study, the composition of α1β3 receptors expressed on the surface of HEK293 cells was
found to form pentamer with a stoichiometry of two α and three β subunits, whereas
combinations of α1γ2 or β3γ2 subunits predominantly form heterodimers (Tretter et al.,
1997).
One possible explanation for the discrepancy between these studies could be the
stoichiometry of the GABAAR pentamers might not be unique. It might vary depending
on receptor subtypes, as suggested from the investigation of native receptor (Li and De
Blas, 1997).
There are six possible subunit arrangement in pentameric receptors consisting of two α,
two β and one γ subunit (see Figure 15.). Among them the first two (Figure 15a and
15b) are believed to be energetically favoured, and consistent with the observation that
α and γ or β and γ subunits predominantly form dimers ( Sieghart et al., 1995; Tretter et
al., 1997).
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Figure 15.
Figure 15. Possible subunit arrangements of receptors composed of two α
subunits, two β subunits and one γ subunit
γ
α
β
A B
C D
E F
α
β
γ
β
βα
α
γ
α
βα
β
γ
β
β α
α
γ
β β
α α
γβ β
α α
63
Section 3. Natural products as a source of new drugs and
pharmacological tools
Throughout the history, natural products have been an important source for both new
drugs and pharmacological tools. This section will first give a general introduction in
this respect, following by an analysis of current status of TCM and the development of
new drugs from TCM medicinal plants.
3.1. Natural products as a source of new drugs
Many clinically useful drugs that currently play a major role in the treatment of various
human diseases are developed from natural sources such as by microbial fermentations
or plant extracts (for review, see Bruhn, 1989; Phillipson, 1994; Cott, 1995; Houghton,
1995; Clark, 1996; Pettit, 1996; Nisbet and Moore, 1997; De Smet, 1997; Shu, 1998).
Atropine, reserpine, Quinine, penicillin G, morphine, digoxin, cyclosporin etc., are the
most well known natural products-originated drugs as milestones in the history of
modern medication. It has been estimated that about half of the best selling
pharmaceuticals were found either natural products or their derivatives, and
approximately 60% of the antitumor and antiinfective agents that are commercially
available or in late stages of clinical trials today are of natural product origin (Table 7;
Cragg et al., 1997). Natural products have not only contributed to the development of
new modern drugs as mentioned above, but also still play a very important role in most
of the developing countries. Thus, it is estimated that 80% of the non-industrialised
world still relies on plants as the major source of medicines in their primary health care
(Farnsworth and Soejarto, 1985; Wijesekera, 1991).
Concerning natural products as source of new drugs, besides the microbial products,
plants are one of the main resources for new drugs or drug candidates. It has been
reported that ca. 120 compounds derived from 90 plant species may be considered as
important drugs currently in use in one or more countries, 77% of which are derived
from plants used in traditional medicine (Table 8; Farnsworth et al., 1985). However,
there are only a small proportion of the estimated 400,000 – 500,000 plant species
around the globe have been phytochemically investigated, and the number for biological
or pharmacological screening is ever lower (Hostettmann et al., 1997). It is urgent to
64
investigate the pharmacology of plant compounds as soon as possible due to the
widespread loss of habitats, especially the tropical forests, which contain the greatest
bio-diversity in the world. It is estimated that more than 60,000 species of flowering
plant will become extinct by the year 2050 (Hamann 1991).
Table 7.  Analysis of origin of 520 new drugs approved by the FDA in USA or
comparable entities in other countries in the period of 1983-1994
Origin of drugsClinical Indication
B N ND S S*
Antiallergic 1 5
Antibacterial 6 44 14
Anticancer and adjuvants 6 4 11 12 4
Antidiabetic 2 2
Antihypertensive 27 25
Antiinflammatory 1 12 27
Antithrombotic 2 3 5
Antiulcer 1 9 11
Antiviral 3 7
Bronchodilator 2 4
Hypocholesterolemic 2 1 1
Immunostimulant 2 3 1 1
Immunosuppressant 1 2 1 1
Nootropic 1 1 6
Platelet aggregation inhibitor 3 1
Progestogen 4
Others 16 9 34 174 5
Total (520) 28 30 127 289 46
Percentage (%) 5 6 24 56 9
B: Biologics, including vaccines, monoclonals etc. N: Natural product from an
unmodified source. ND: Natural product derivatives. S: Synthetic. S*: Synthetic,
modelled on a natural product parent. Modified from Cragg et al., 1997.
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Table 8. Representative drugs with plant origin (Farnsworth et al., 1985)
Drugs Clinical uses Source
Atropine Anticholinergic Atropa belladonna
Caffeine CNS stimulant Camellia sinensis
Cocaine Local anaesthetic Erythroxylum coca
Codeine Analgesic, antiussive Papaver somniferum
Colchicine Antigout Colchicum autumnale
Digitoxin Cardiotonic Digitalis purpurea
Digoxin Cardiotonic Digitalis lanata
Ephedrine Sympathomimetic Ephedra sinica
Gossypol Male contraceptive Gossypium herbaceum
Hyoscyamine Anticholinergic Hyoscyamus niger
Kawain Tranquilliser Piper methysticum
Levodopa Antiparkinsonian Mucuna deeringiana
Morphine Analgesic Papaver somniferum
Noscapine Antiussive Papaver somniferum
Ouabain Cardiotonic Strophanthus gratus
Pilocarpine Parasympathomimetic Pilocarpus jaborandi
Quinidine Antiarrhythmic Cinchona ledgeriana
Quinine Antimalarial Cinchona ledgeriana
Reserpine Antihypertensive Rauvolfia serpentina
Scopolamine (hyoscine) Sedative Datura metel
Tubocurarine Muscle relaxant Chondrodendron tomentosum
Vinblastine Anticancer Catharanthus roseus
Vincristine Anticancer Catharanthus roseus
Yohimbine Aphrodisiac Pausinystalia Yohimbe
The most notable progress in identification of new drugs from plants has been made in
the area of chemotherapy of cancer (Wall and Wani, 1995; Pettit, 1996; Cragg et al.,
1997; Kinghorn et al, 1998; Pezzuto et al., 1998). For example, the two alkaloids
vincristine and vinblastine, isolated from catharanthus roseus, are important therapeutic
compounds for the treatment of acute childhood leukemia (vincristine), Hodgkin’s
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disease and metastatic testicular tumours (vinblastine) (Nelson, 1982; Baker et al.,
1995). Their semisynthetic derivative vinorelbine exerts antitumor effect by tubulin
binding leading to inhibition of microtubule assembly, thus are used for the treatment of
advanced breast cancer (Sorensen, 1995). Two important additions to the cancer
chemotherapeutic list are etoposide and teniposide, the semisynthetic derivatives of
podophyllotoxin, which was originally isolated from plant Podophyllum peltatum (may-
apple) (Buss and Waigh, 1995). Etoposide is active against many tumour types and one
of the most active single agents for small cell lung cancer, while teniposide is used for
the treatment of refractory acute lymphoblastic leukaemia in children (Buss and Waigh,
1995). The most exiting advance in cancer chemotherapy would be the discovery of
paclitaxel (taxol). In the large scale-screening programme of American National Cancer
Institute initiated some 40 years ago, thousands of extracts of randomly selected plants
were tested for cytotoxic activity. Paclitaxel was identified as the active component of
the crude extract from the stem bark of Taxus brevifolia (Pacific yew), and showed
activity against many tumours (Wall and Wani, 1995). It was approved for the treatment
of ovarian cancer and breast cancer in 1992 and 1993, respectively. The ability of taxol
to polymerise tubulin into stable microtubules in the absence of any cofactors and to
induce the formation of stable microtubule bundles in cells characterised taxol as unique
antitumour drug with microtubules as the new target of action (Horwitz, 1992).
Docetaxel (taxotere), a semisynthetic derivative of 10-deacetylbaccatin III, which is
isolated from the needles of Taxus baccata (European yew), is closely related to taxol
with improved water solubility and similar action against various tumours. It is the most
active single agent against metastatic breast cancer (Crown, 1998).
3.2. Natural products as a source of pharmacological tools
While natural products have served and still will serve as a important source of new
drugs, another important role of natural products in medical research is that they can be
used as pharmacological tools for the identification and investigation of the
physiological functions of receptors and enzymes, which serve or possibly will serve as
drug targets. For example, nicotine, physostigmine and curare have made a great
contribution to the research of the nicotinic receptor. The same is true for muscarine,
pilocarpine to the muscarinic receptor. In the field of intracellular signal transduction,
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for example, has been developed, in large part, through the study of cyclopsorin, FK506
and rapamycin,  (Cardenas, et al., 1998). The phorbol esters from the Euphorbiaceae or
Thymelaeaceae families have played a very important role in the investigation of the
protein kinase C and have contributed to the identification of a further receptor RX-
kinase (RX is the C-20 homovanillate of 9,13,14-orthophenylacetyl-resiniferonol).
These enzymes are of importance in the understanding of disease conditions such as
inflammatory response, cancer, cell proliferation, viral expression etc. (Evans, 1991).
For the GABAARs, the research process might be different without the contribution of
muscimol, bicuculline and picrotoxin, all of which are natural products. Some
representatives of compounds from natural sources as important pharmacological tool
are shown in Table 9.
Table 9. Representative compounds with natural origin as important
pharmacological tool for neurotransmitter receptors, neuropeptid receptors and
enzymes
Receptors Compounds Origin
Nicotinic Ach receptor
Acetylcholinesterase
inhibitor
Physostigmine Physostigma venenosum
Agonist Nicotine Nicotiana tabacum etc.
Arecoline Areca catechu
Antagonist d-tubocurarine Chondrodendron tomentosum
Muscarinic Ach receptor
Agonist Muscarine Amanita muscaria (fungus)
Pilocarpine Pilocarpus jaborandi
Arecoline Areca catechu
Antagonist Atropine Atropa belladonna
Scopolamine Datura metel
Anisodine Anisodus tanguticus
Anisodamine Anisodus tanguticus
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Table 9. continued
GABAAR
Agonist Muscimol Amanita muscaria
Competitive antagonist Bicuculline Corydalis humosa
Dicentra cucullaria
Non-competitive
antagonist
Picrotoxin Anamirta cocculus
Glycine receptor
Antagonist Strychnine Strychnos nux-vomica
NA receptor
Selective α-2 receptor
antagonist
Yohimbine Pausinystalia Yohimbe
NA, DA, 5-HT receptor
Vesicular transport and
storage inhibitor
Reserpine Rauvolfia serpentina
Opioid receptor
µ subtype agonist Morphine Papaver somniferum
Adenylate cyclase
Activator Forskolin
(colforsin)
Coleus forskohlii
Protein kinase C
Activator Phorbol esters Euphorbiaceae or thymelaeaceae
families
3.3. Medicinal plants in TCM
3.3.1. The general status of TCM
TCM is an integral part of the Chinese culture. Over the past several thousand years, it
has made great contributions to the health care of Chinese nation through out the
history, and still plays a important role in the modern China. Its remarkable efficacy,
accumulated experiences and available historical literature make it an important source
for new drug development research in China. TCM is one of the dual medical systems
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running in China along with the Western medicine. An overview of the current status of
TCM in China is presented in Table 10.
Table 10. A general status of TCM in China∗
Administration State Administration of TCM (equivalent to State
Administration of Medicine and Pharmacy for the Western
medicine )
Hospitals 2457 TCM hospitals, 39 hospitals of integrated Western and
Traditional Chinese Medicine, 129 hospitals of national
minorities medicine, 75% counties have TCM hospital
222,000 beds, 249,000 TCM doctors.
Education 30 TCM universities with a enrolment of 37,000 students
51 TCM colleges with 29,000 students
64,000 people educated from TCM night school,
correspondence schools etc.
Research 77 independent national research institutions
100 institutions affiliated to TCM universities, colleges and
provincial hospitals
10,000 academic professionals
Pharmaceuticals 500,000 employees
600 productive bases, 13,000 farms and 340,000 specialised
households for crude drugs production, with a planting area
of 5,220,000 mu (1 mu = 667 m2 )
800 TCM pharmaceutical companies
40 forms, 5000 varieties with 200,000 ton yearly yield
3.87 billion yuan output value (1 yuan = 0.8 Danish krone)
∗ Data is based on a review of TCM history appeared on the official Web site of China
Academy of TCM (http://china-window.com/zhongy/zydl/e_zyls.html). Figures are
referring to that in 1993.
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3.3.2.   TCM medicinal plants as a source of new drugs
The Materia Medica of TCM includes substances from plants, animals and minerals. A
nationwide survey of Chinese herbal medicine (CHM) covering 80% of China's land
area conducted over a period of five years from 1983 revealed that there are now 12,807
medicinal agents in the Chinese Materia Medica: 11,146 of plant origin, 1,581 of animal
origin, and 80 from mineral sources (Zhang et al., 1995). According to the ways they
are used, CHM can be classified into three main categories: 1). TCM herbal medicine.
they are used by TCM doctors. Their usage are directed by the systematic and self-
contained TCM theories. They are the main component of the CHM and comprise ca.
50% of that commonly used totally. 2). National minorities drug. They are used by
doctors of various national minorities of which Tibetan, Mongolian are the most
important ones. They are all closely connected with TCM, but have their own
characteristics. 3). Folk herbal drugs. They are scattered throughout China with a large
number, and are characterised by application on the basis of trial and error without
theoretical direction. Some of the truly effective herbal drugs and prescriptions are
being kept secret, open only to the owners and to be taught only to their descendants or
favourite apprentices.
Concerning the new drug development process, there are mainly two different ways to
develop new drugs from TCM substances. The first way, basically according to the
standard of that in the Western countries, used single compound, identified from TCM
plants or its derivatives with profound activity (e.g. Artemisinin against malaria). The
going-through procedures include: 1). Conclusively approving of the compound
structure; 2). Production technology of the compound. 3). Animal toxicity experiment
(acute and long term); 4). Pharmaceutical experiment on animal model. 5). Animal
pharmacodynamic experiment; 6). Stability experiment of the preparation. 7). Clinical
trials. 8). Government census. The drugs developed in this way are classified as first
class drugs. The second way, which is unique in China, is to develop drugs from TCM
prescriptions. These prescriptions could come from an ancient known literature, an
experienced TCM expert or a secret formula from an ethnical group etc., but the
prerequisite is a profound clinical effectiveness. Going through a similar but fewer
procedures, the developed drugs are classified as second or third class drugs. Although
the exact knowledge of the active components of these drugs are unknown (there could
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be hundred and thousands of compounds in it), the quality control were achieved by
setting up a standard for the major known active compounds (which has been shown
responsible for the relevant pharmacology by use of modern medicine methods)
appeared in the herbs composing the prescription. The standard is set up by using
modern analytical methods as HPLC, mass spectroscopy, atomic absorption
spectrophotometry, ultraviolet spectrophotometry, infrared spectrophotometry and
NMR etc. In a similar way, a huge amount of on-the-counter products (similar to the
Ginkgo biloba products in the Western) from CHM were produced for the purpose of
general health care like tonic, cosmetic, weight-reducing etc.
Extensive research has been done on the basic pharmacology of Chinese medicinal
plants and their products. These researches including 1). Botanical classification and
differentiation of medicinal plants; 2). Microscopic, chromatographic and chemical
identification standards for medicinal plants; 3). Identification and characterisation of
active constituents; 4). Pharmacological investigation of the active constituents in
appropriate in vitro and in vivo experimental models (A book about all animal models
used in TCM has been compiled by me and my Chinese colleagues. Chen et al, 1993);
5) Pharmacokinetic, pharmacodynamic and toxicological studies. 6). Investigation of
the processing of TCM crude drugs. The results are predominantly published in Chinese
(e.g. The handbook of active components of Chinese herbal medicine, compiled by
Jiang and Xiao, 1986 included all the compounds isolated from CHM by then. The
handbook of chemical components and pharmacology of most commonly used Chinese
herbal medicine, compiled by Huang, 1993 with 1900 pages reviewed 429 plants in
detail on different names in the literature, botanical identity, commercial available
forms and quality standards, brief description of traditional use, general, microscopic
and physiochemical identification, known chemical components and pharmacology).
Over the years, many drugs or promising drug candidates have been identified from
CHM, some representative ones are listed in Table 11.
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Table 11. Representative examples of Chinese plants-originated drugs or drug
candidates∗
Drugs Origin Indications or functions
5,7,3’,4’-
tetrahydroxyflavone-3-
nol C4-C6 dimer
Fagopyrum cymosum Pulmonary abscess
α-dichroine
β-dichrooine
Dichroa febrifuga Malaria
Agrimorphol Agrimonia pilosa Taeniasis
Anisodamine Anisodus tanguticus Fulminant epidemic
meningitis, hemorrhagic
enteritis
Anisodine Anisodus tanguticus Migraine, organophosphorus
poisoning, acute paralysis
caused by vascular accident
Artemisinin
Artemether∗∗
Arteether∗∗
Artesunate∗∗
Dihydroartemisimin ∗∗
Artemisia annua Malaria
Camptothecin
Ironotecan∗∗
Camptotheca acuminata Lung, ovarian and cervical
cancers
Curcumol
Curdione
Curcuma aromatica Early stage of cervix cancer
Daizin
Genistin
Daidzein
Pueraria lobata
(Chinese Kudzu)
Alcoholic
Hypertensive disease, angina
pectoris, migraine and sudden
deafness (daidzein)
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Table 11. continued
Gastrodin Gastrodia elata Insomnia, anxiety and
vertigo
Schisandrin A, B, C
Schisandrol A, B
Schisantherin A, B, C
Schisandra chinensis
Schisandra sphenanthera
Hepatitis
Gossypol Gossypium herbaceum
(Cotton seed)
Male contraceptive
Homoharringtonine Cephalotaxus harringtonia
Cephalotaxus fortunei
Leukaemia
Houttynin Houttuynia cordata Antimicrobial, for infections
Huperzine A Huperzia serrata Alzheimer’s disease
Indirubin Indigofera tinctora
Baphicacanthus cusia
Isatis tinctoria
Couroupita guianensis
Chronic myecytic leukemia
Methyl hydroquinone Pyrola rotundifolia For infections in respiratory,
digestive and urinary system
Nevadensin Lysionotus pauciflorus Expectorant, antiussive,
antituberculosis
Piperine
Antilepsirine∗∗
Piper nigrum Epilepsy
Rubescensin (oridonin)
Ponicidin
Rabdosia rubescens Esophageal and liver cancer
Terpenoids Brucea javanica Malaria
Triptolide Tripterygium wilfordii Rheumatoid arthritis
Tutin Coriaria sinica
Loranthus parasiticus
Schizophrenia
Yingzhaosu A
Arteflene∗∗
Artabotrys uncinatus Malaria
Yuanhuacine A and B Daphne genkwa Induces premature abortion
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∗ Data are collected from reviews (Xiao, 1983; Jiang and Xiao, 1986 (Chinese); Tang
and Eisenbrand, 1992; Wang et al., 1995; Clark, 1996; De Smet, 1997; Zhu et al.,
1996b; Qin and Xu, 1998; Shu, 1998; Huang, 1999).
∗∗ Synthetic derivatives
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Section 4: Medicinal plants as a source of novel brain GABAA/BZD
receptor ligands- The experimental work
As discussed above, natural products, especially medicinal plants are important source
of new drugs and pharmacological tools. The apparent side-effects associated with the
use of classical BZDs, the promising profiles of BZD receptor partial agonists, the lack
of high selective ligands for the BZD receptor subtypes, as well as the possible
existence of other binding sites as potential drug targets on the GABAA/BZD receptors
motivate chemists, biochemists and pharmacologists all over the world to seek and
develop compounds with advantageous or new pharmacological profiles and/or new
chemical structures.
One line of development is to isolate GABAA/BZD receptor ligands from natural
sources by bioassay-guided fractionation. Special effort has been to isolate these
compounds from medicinal plants used in traditional or folkloric medicine as TCM.
The purpose of current work is to combine the knowledge advantage of TCM medicinal
plants with the strategies for developing GABAA/BZD receptor ligands, to isolate and
characterise GABAA/BZD receptor active compounds from TCM plants as well as from
semi-synthesised naturally-occurring compounds by using methods as HPLC, radio-
ligand binding assays and electrophysiology etc.. Based on our own experiences, some
general strategies and methodologies of identifying compounds from medicinal plants
will be illustrated. The results of our screening work and some possible pitfall will be
discussed.
4.1. General methodology in identifying GABAA/BZD receptor ligands from
TCM plants
The discovery process for biologically active natural products involves a number of
particular steps included: 1). The selective identification of a biological target (e.g.
GABAARs in the brain). 2). The selection, collection and identification of the organisms
to be studied (e.g. plants, marine organisms, fungi, etc.). 3). The extraction and
biological evaluation of the extracts. 4). Set priority for further studies. 5). Bio-activity-
directed fractionation of the extracts and the structure elucidation of the biologically
active principles. 6). Biological evaluation and mechanistic studies of the isolates. 7).
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Synthetic modification and molecular modelling studies with the anticipation of
identifying the pharmacophoric units. 8). A strategic decision for further development
(see Figure 16, Cordell et al., 1998).
Using the GABAA/BZD receptor-binding assay as primary screening method, new
structurally diverse ligands were isolated and identified from medicinal plants ( see
Appendix I for overview).
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Figure 16.
Figure 16. The general procedure for identification of GABAA/BZD receptor
ligands from plants.
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4.2.  Materials and Methods
4.2.1. Materials
Isotopes and chemicals: Radioactive ligands [3H]diazepam (methyl-[3H], 83 Ci/mmol),
[3H]Ro 15-1788 (N-methyl-[3H], ethyl 8-fluoro-5, 6-dihydro-5-methyl-6-oxo-4H-
imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate, 87 Ci/mmol), [3H]muscimol
(methylene-3H (N), 20 Ci/mmol), [35S]TBPS (t-butylbicyclophosphoro-[35S]-thionate),
[3H]SCH 23390 (N-methyl-3H, 71.3 Ci/mmol) and [3H]QNB ([3H]quinuclidinyl
benzilate (L-[benzilic-4, 4’-3H(N)], 43.5 Ci/mmol), and  [3H]kainic acid (62.5
Ci/mmol) were from New England Nuclear, Dupont (Boston, MA, U.S.A.).
All HPLC solvents were from Rathburn Chemical (HPLC grade). Tested flavonoids
were from Extrasynthese, Genay, France. Honokiol and magnolol were from Nacalai
Tesque Inc. Japan and The Institute of Drug Identification, Beijing, China.
GABA and Diazepam were purchased from Research Biochemicals International,
Natick, U.S.A..
Plants: Plants were purchased from The pharmacy of China Academy of TCM in
Beijing, and identified by Dr. S.J. Xu.
4.2.2. Methods
Preparation of rat brain membranes: The radioreceptor binding assays were carried
out as previously described [Nielsen et al., 1988; Witt and Nielsen, 1994;
Dekermendjian et al., 1996; Ai et al., 1997a, c; Ai et al., 1999]. In brief, male Wistar
rats (weighing about 200 g) were decapitated, the cortex, hippocampus and cerebellum
were rapidly excised and homogenised using an Ultra Turrax homogeniser in Tris-
citrate buffer (50 mM, pH 7.1), followed by centrifugation (30,000 × g, 10 min). This
washing procedure was repeated 3 times. The last pellets were stored at -24o C until use.
After thawing, the pellet was resuspended in Tris-citrate buffer, subjected to one
additional washing step and diluted to a concentration of 2 mg original tissue/ml for the
binding assays.
[3H]diazepam, [3H]flunitrazepam and [3H]Ro 151788 binding assays: Aliquots of 1 ml
membrane preparation were incubated with [3H]diazepam (2 nM), [3H]flunitrazepam (1
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nM) or [3H]Ro-151788 (1.2 nM) for 40 min at 40 min at 0-4o C. For saturation assays, 6
to 9 concentrations of [3H]Ro 15-1788 (0.05-15 nM) or [3H]diazepam (0.2 – 10 nM)
were used. Non-specific binding was determined by addition of midazolam (10 µM) or
Ro-151788 (100µM).
[3H]muscimol binding assays: Assays was conducted on washed-frozen-washed
membrane preparation. Aliquots of 1 ml membrane preparation were incubated with
[3H]muscimol (10 nM) for 30 min at 0-4o C. In saturation experiments 6 to 9
concentration of [3H]muscimol (0.2 – 25 nM) was used. Non-specific binding was
determined by addition of GABA (100µM) in the assay.
[35S]TBPS binding assays: For [35S]TBPS binding, the pellet containing cortical
membranes was washed once with Tris-citrate buffer (50 mM, pH 7.1) and centrifuged.
The pellet was resuspended in Tris-citrate buffer containing NaCl (1M) to a
concentration of 10 mg original tissue/ml and assayed (0.5 ml assay volume) for
specific [35S]TBPS (0.9 nM) binding. Non-specific binding was obtained by incubation
of 50 µM picrotoxinin. For TBPS on-rate experiments, incubations were done at 25 oC
varying the incubation time from 20 to 240 min.
[3H]QNB binding assays: In the [3H]QNB (1.5 nM) binding assays, rat brain cortical
membrane was prepared and used in the same way as in [3H]muscimol binding assays.
Unspecific binding was determined by including 10 µM atropine. Samples were
incubated at 37 °C for 60 min.
[3H]SCH 23390 binding assays: [3H]SCH 23390 (0.25 nM) binding assays were
performed on membrane preparation of rat brain striata as previously reported
(Dekermendjian, et al., 1997). Briefly, Striata were dissected and rapidly homogenised
(Ultra Turrax, 10 s) in 50 mM KH2PO4 buffer pH 7.4 and centrifuged at 30,000 g for 10
min. The pellet was resuspended in 50 mM KH2PO4 buffer pH 7.4 at a concentration of
1 mg tissue/ml, [3H]SCH 23390 was added to aliquots of 1 ml homogenate and
incubated for 60 min at 30°C.
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[3H]kainic acid binding assays: The binding assays were carried out as previously
described (Andersson et al., 1995). Briefly, [3H]kainic acid (2 nM) was added to
aliquots of 0.5 ml membrane preparation (final concentration of 20 mg original
tissue/ml), and incubated for 60 min at 0 – 4 °C. Non- specific binding was determined
by adding L-glutamate (600 µM).
All binding assays were terminated by vacuum filtration through Filter Max filters using
Semiautomatic Cell Harvester (Skatron Instrument, UK), or through Whatman GF/C
glass filters. Filters with bound ligand were washed twice with ice-cold Tris-citrate
buffer (50 mM, pH 7.1). Radioactivity on the filters was measured in 3 ml of
scintillation fluid. Specific binding was calculated by subtracting non-specific binding
from total binding. All binding assays were done in duplicate.
GABAA/BZD receptor expression in Sf-9 insect cells for receptor binding: The
expression of recombinant GABAA/BZD receptor subtypes using the Sf-9/baculovirus
expression system was previously reported [Witt et al., 1996]. In brief, Sf-9 insect cells
were grown in Sf 900 medium at 27 o C to a cell density of approximately 1 x 106
cells/ml (200 ml batches) and infected with baculovirus containing cDNA for various α
(α1, α2, α3 and α5) and the β (β2 and β3) and γ2S subunit with a MOI (Multiplicity Of
Infection) value of 1:1:1. Cells were harvested by centrifugation approximately 45 hours
post infection for receptor binding assays or kept as pellets at -80o C until use.
Preparation of Sf-9 insect cells for binding assays: Sf-9 cells (30 x 106 /ml) were
homogenised in 5 ml Tris-citrate buffer (50 mM, pH 7.1) using an Ultra-Turrax
homogeniser and centrifuged (30,000 x g, 10 min). The pellet was resuspended in 1.5
ml of Tris-citrate buffer, incubated at 37o C for 30 min and centrifuged, followed by two
further washes in Tris-citrate buffer. The final pellet was resuspended in Tris-citrate
buffer to give a concentration of 106 cells/ml and used for binding assays. The
determination of non-specific binding, the incubation conditions and the termination of
the assays for different radio-ligands were carried out in the same way as described
above.
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Data analysis: All binding data was analysed using linear regression and statistic
significance was obtained using student’s t-test.
Electrophysiology: The experimental set-up and solutions used in electrophysiological
experiments are described in detail in Appendix II. In electrophysiological
experiments, all compounds were dissolved in the external solution just before use.
Selection of plants and compounds: There are two ways to start the screening. One way
is to select plants by their confirmed effectiveness as sedative, anxiolytic, anti-
convulsive and anti-epilepsy according to the TCM clinical literature. Although these
plants were chosen as a single plant for the screening work, most of them are the main
elements of known prescriptions which possess the above mentioned clinical properties.
For example, Pseudostellaria heterophylla was chosen for screening from a known
Chinese prescription named Kangdianling (Panacea of anti-epilepsy). Angelica
dahurica was identified from a secret anti-epilepsy prescription containing 10 plants
donated by a known TCM doctor in Beijing.
 Another way to identify compounds from TCM plants is to screen compounds (or plants
containing the compounds) which were reported to have CNS activities in vivo. Due to
various reasons, e.g. the general lack of sensitive detecting systems like the receptor or
receptor subtypes selective radio-ligand binding assay, a large number of studies have
used purified or semi-purified compounds in in vivo studies rather than in vitro
experiments. Since most of these data is published exclusively in Chinese language, it is
not available for the scientists in western countries. In the book of Jiang and Xiao (1986)
alone, there are more than one hundred compounds showing analgesic, anticonvulsive,
anxiolytic, sedative and hypnotic effects. We did not conduct the investigation in this
way yet, but it would potentially be a rewarding source to seek active compounds for
specific CNS receptor systems.
 
 Extraction and preliminary separation of plant extracts by HPLC: All plants (5 g)
were extracted with 50 ml 50% ethanol (volume/volume) for 24 hrs in room temperature
(ca. 23 o C). Plants were cut to small pieces and homogenised by using Ultra Turrax
homogeniser. The homogenate was extracted for another 24 hrs by standing in room
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temperature. The extractions were terminated by a gravity filtration (Whatman no. 1
filter paper). The extracts (equivalent to ca. 500 mg original dry plants per tube) were
lyophilised at reduced pressure.
 The dried extracts were re-dissolved in 5 ml acetonitrile (CH3CN)/water (25%/75% v/v),
and 0.5 ml of the solution was applied to Waters HPLC, C18 Delta-Pak 3.9 × 150 mm
analytic reverse phase column at flow 1.2 ml/min using linear gradient from 25% to
100% acetonitrile (75% to 0% of water) within 50 minutes under UV detection (210
nm). A linear gradient from 0% to 100% acetonitrile (Water run, 100% to 0% of water)
were used for the fractions, which came out at the very beginning of the previous HPLC
and was found active in the [3H]muscimol binding. Usually, these fractions are
considered as GABA it self. 1 min fractions were collected and lyophilised for binding
assays. 25 µl 93% ethanol were added to fractionated plant samples as well as control
samples in the screening binding assays. Because the drugs determining the non-specific
binding were dissolved in 93% ethanol, 25 µl Tris-citrate buffer were added to these
samples in the binding assays.
4.2.3. Approaches for biochemical and pharmacological characterisation of active
compounds
IC50: IC50 is the concentration of compounds causing 50% inhibition of radioligand
specific binding to the receptors. The IC50 values is determined by including a range of
concentrations of a compound (e.g. 10 nM to 100 µM) in the given receptor binding
assay carried out with a fixed concentration of radioligand and membrane preparation.
This value is used to evaluate the potency of a purified substance at the relevant receptor
or binding sites.
 
GABA-ratio:  Due to the allosteric interaction, GABA and GABAA receptor agonists
can modulate the binding affinity of BZD site ligands as tested by [3H]BZD binding
assays. GABA enhances, has no effect or reduces the affinity of BZD site agonists,
antagonists and inverse agonists, respectively. Accordingly, GABA produces a shift of
the dose-response curve to the left, no change or to the right for BZD site agonists,
antagonists and inverse agonists, respectively. Thus, GABA-ratio (or GABA shift) is
considered as a indicator for the efficacy of BZD site (receptor) ligands. The GABA-
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ratio is defined as the IC50 value of compound inhibiting the [3H]BZD specific binding in
absence of GABA divided by the IC50 value in presence of GABA (usually 100 µM) in
the binding assays. In general, full agonists give a ratio ≥ 2, partial agonists have a ratio
between 1 and 2, antagonists have a ratio around 1, partial inverse agonists give a ratio
between 1 and 0.5, while full inverse agonists have a ratio ≤ 0.5.
Scatchard plot analysis: In order to determine the nature of action (competitive or non-
competitive) for a substance with a binding site, saturation binding experiments are done
in the presence or absence of the compound.  Scatchard plot is a standard method for
deriving equilibrium binding parameters (Affinity binding constant, KD; and maximal
concentration of binding sites, Bmax) from saturation binding data. A range of radio-
ligands (e.g. 0.2 – 10 nM for [3H]diazepam, 0.05 – 15 nM for [3H]Ro 15 1788 and 0.2 –
25 nM for [3H]muscimol binding) are included in the binding assays. Protein was
estimated spectrophotometrically using the Bio-Rad DC Protein Assay Kit, using bovine
serum albumin as standard.
Determination of the selectivity: Different subtype of the GABAARs has a distinct
distribution in the brain. The primary tests on different brain region will show whether a
purified compound will have potential receptor subtype selectivity. With this
information, the subsequent tests on the different subunit combinations of the
recombinant GABAARs will further verify its selective activity.
Functional characterisation: Functional characterisation of the active compounds can
be achieved by directly measuring the Cl- currents induced by the compounds on
baculovirus/Sf9 cell system expressing recombinant GABAARs using the whole-cell
patch- clamp technique. Combining and comparing these data with data from the
receptor binding assays, it is possible to thoroughly characterise the active compounds in
vitro.
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4.3. Results and Discussion
4.3.1. Results of the isolation and characterisation of active compounds from
TCM plants
4.3.1.1.    An overview of the screening results
Table 12. Summary of plants screened for CNS activity in vitro ∗
Chinese
Name
Latin name [3H]flunitrazepa
m
[3H]muscimol Compounds
purified
Baijiang Patrinia villosa 4–10 min
40% ↓
0
Baijuihua Chrysanthemum
morifolium
12, 15 min ↓ × Acacetin
(IC50 ∼ 20 µM)
Baizhi Angelica dahurica ↓↓ 0 Phellopterin
byakangelicol
imperatorin
(Appendix III)
Cangzhu Atractylodes chinensis 25 min 50% ↓ 25 min 207%↑
Chaihu Bupleurum chinense 0 0 15, 20, 25 min ↓
[3H]kainic acid
Saikosaponin A
Saikogenin G
(IC50 ∼ 50 µM)
Dahuang Rheum palmatum 0 Water run
3, 4, 6 min ↓
Gualou Trichosanthes kirilowii 4, 10, 15, 20 min
↓↓
×
Houpo Magnolia officinalis 15, 20 min ↓
23 min ↑
15, 20 min ↑ 23
min ↑
Honokiol, magnolol
(Appendix IV)
Shengma Cimicifuga foetida 0 0 Cimicidanol
([35S]TBPS ↓)
IC50 ∼ 4 µM
Taizishen Pseudostellaria
heterophylla
Ca. 20 active
compounds ↓↓↓
0 βCCE, βCCM
Wuzhuyu Evodia rutaecarpa 22 – 27 min ↓ 0 Rutaecarpine
(IC50 ∼ 1µM)
Xinyi Magnolia liliflora × 6 min 300% ↑
Yanhusuo Corydalis yanhusuo 0 20-22 min 50% ↓
Single peak
It could be
bicuculline
∗ 0 = no effect; × = no assay; ↓, ↓↓, ↓↓↓ = representing 40 to 60%, 60 to 80%, and 80
to 100% inhibition of the specific binding in the corresponding binding assays,
respectively. ↑ = enhancing effect. The retention time was from the HPLC running
linear gradient from 25% to 100% acetonitrile (75% to 0% of water) or from 0% to 100
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% acetonitrile (Water run) within 50 minutes using UV detection (210 nm) on Waters
HPLC, C18 Delta-Pak 3.9 × 150 mm analytic reverse phase column at flow 1.2 ml/min.
It has been generally realised that if the selection of plants were made on the grounds of
their traditional usage, the chances for finding positive activity would be greater (Brito,
1996). In our current screening project, totally ca. 50 TCM plants were screened mainly
for their activity to the various binding sites (GABA, BZD and TBPS binding sites) on
the GABAARs using in vitro radioligand-receptor binding assays (except some of the
plants have also been tested against kainate receptor). Activities were found in 13
plants. 12 active compounds from 7 plants were purified and chemically elucidated (see
Table 12). Because of the lower affinity found in the primary experiment, some of the
active compounds (acacetin, rutaecarpine) were not investigated further.
Table 13. Plants with no activity found ∗
Chinese Name Latin Name Chinese Name Latin Name
Huoxiang Agastache rugosa Longdanchao Gentiana scabra
Gaoliangjiang Alpinia officinarum Zaojia Gleditsia sinensis
Binglang Areca catechu Baimaogen Imperata cylindrica
Madouling Aristolochia contorta Nuzhenzi Ligustrum lucidum
Yinchenhao Artemisia capillaris Roudoukou Myristica fragrans
Xixin Asarum heterotropoides Hangbai Phellodendron amurense
Shayuanzhi Astragalus complanatus Huhuanglian Picrorhiza Kurrooa
Chaojueming Cassia tora Biba Piper longum
Guizhi Cinnamomum cassia Jiegeng Platycodon grandiflorum
Rouchongrong Cistanche salsa   Heshouwu Polygonum Multiflorum
Shechuangzi Cnidium monnieri Qiancaogen Rubia cordifolia
Yiyiren Coix lachryma-jobi Dingxiang Syzygium aromaticum
Xiaohuixiang Foeniculum vulgare
∗ No activity are found in radioligand-receptor binding assays of [3H]muscimol,
[3H]flunitrazepam and [35S]TBPS binding to rat cortical cortex membrane preparation.
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4.3.1.2.       The characterisation of phellopterin
Angelica dahurica is used as an antipyretic and analgesic for cold, headache, and
toothache in traditional Chinese medicine and it is known to contain a large number of
coumarins and furanocoumarins. The furanocoumarin derivatives phellopterin,
byakangelicol and imperatorin were purified from Angelica dahurica (see Appendix
III). Phellopterin, the most potent one (determined as comparing of the IC50s) among
the three derivatives, was found inhibiting [3H]diazepam and [3H]Ro 15-1788 binding to
the BZD binding site of the rat brain GABAAR in vitro with IC50 values of 400 and 680
nM, respectively. The GABA ratios of 1.3 for [3H]diazepam binding and 1.7 for [3H]Ro
15-788 binding indicate that phellopterin is a partial agonist at the BZD site. This
finding was supported by TBPS shift experiments. Scatchard plot analysis showed that
phellopterin increased the KD without changing the Bmax in [3H]diazepam binding to
various rat brain membrane preparations, which indicate a competitive inhibition of
phellopterin. As discussed in Section 1, the partial agonist is more favourable for the
development of new generation of anxiolytics as compared to full agonist for their
lower intrinsic efficacy. This partial agonistic nature makes phellopterin a more
interesting lead for developing active derivatives at the BZD site.
4.3.1.3. The isolation and characterisation of honokiol and magnolol
Two parts of work have been done on the characterisation of honokiol and magnolol.
The first part of the work present here was done in this laboratory. The second part of
work was done in collaboration with Dr. Squires in USA (Appendix IV).
The isolation and purification of honokiol and magnolol: Batches of the root from
Magnolia officinalis were extracted by 10 volumes of ethanol 50% (volume/volume)
(e.g. 5 g plant in 50 ml ethanol) for ca. 24 hours at room temperature and homogenised
by an Ultra-Turrax homogeniser. The homogenate was further extracted for 24 hours at
room temperature. The extractions were terminated by a gravity filtration and the
ethanol extracts were lyophilised at reduced pressure. Samples (corresponding to ca.
500 mg original plant/tube) were re-dissolved in a mixture of acetonitrile/water
(CH3CN/H2O, 25%/75%).  Compounds in the extract were applied (in amounts
corresponding to ca. 50 mg original plant material) and separated on a HPLC, C18 Nova-
Pak reverse phase column (3.9 × 150 mm) at flow rate of 1.2 ml/min using linear
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gradient (25% to 100% of CH3CN/75% to 0% of H2O) within 35 min using UV
detection (210 nm). Fractions with retention times of 20 min and 22 min contained
compounds that showed enhancing effect of [3H]muscimol binding a membrane
preparation from rat cortex. The fractions were pooled separately and applied to the
same HPLC column at flow 1.2 ml/min using 42% isocratic ratio of CH3CN/ H2O, and
two fractions with retention times of 12 min, 19 min were collected containing
enhancing activity of [3H]muscimol binding. The chemical structures of purified
compounds were identified as honokiol and magnolol using NMR spectroscopy and
Mass spectrometry by Prof. Olov Sterner in Division of Organic Chemistry 2, Lund
University, Sweden.
Pharmacological characterisation of honokiol and magnolol: After the structure
elucidation of the purified honokiol and magnolol, the work of pharmacological
characterisation was done using pure honokiol and magnolol obtained from Nacalai
Tesque Inc. Japan and The Institute of Drug Identification, Beijing, China (the purity
from different batches of honokiol and magnolol was checked by HPLC, corresponding
to more than 98% of the compounds).
Honokiol and magnolol (0.02 ∼ 0.6 mM), in a concentration dependent manner, showed
enhancement of [3H]muscimol binding various membrane preparations (Figure 17a,
17b, 17c and 18a, 18b, 18c). At concentration higher than 2mM, both honokiol and
magnolol fell out of assay binding buffer solution, therefor at these high concentration
the compounds may have unspecific inhibition of [3H]muscimol or [3H]flunitrazepam
binding to rat brain membrane preparations as well as to various human recombinant
GABAA receptor subunit combinations expressed in Sf-9 insect cells. Thus, the
maximum enhancing effects of honokiol and magnolol are not available.
Honokiol and magnolol have similar enhancing effects on [3H]muscimol binding to
cortical and hippocampal membrane preparations; both substances show no enhancing
effect on [3H]muscimol binding to cerebellar membrane preparation. (Figure 17a and
18a).
In the binding assays using membrane preparation of various human recombinant
GABAA receptor subunit combinations, honokiol and magnolol show a significant
enhancing effect on [3H]muscimol binding to all the six subunit combinations tested
(α1β2γ2S, α1β2, α2β3γ2S, α2β3, α3β3γ2S, α5β3γ2S; Fig. 17b, 17c and 18b, 18c). Within
88
these six GABAA receptor subtypes, a more potent enhancing effects of honokiol and
magnolol was found on [3H]muscimol binding to the subunit combinations containing
the α2 subunit (α2β3γ2S and α2β3); while a less potent enhancing effect was found on
[3H]muscimol binding to the subunit combination of α5β3γ2S (Figure 17b, 17c and 18b,
18c).
Saturation binding experiments showed that honokiol (200 µM) significantly increased
both the binding affinity (decrease in affinity constant, KD) and the number of
maximum binding sites (Bmax) of [3H]muscimol binding to subunit combinations
containing α1 subunit (Table 14). Honokiol markedly increased the maximum binding
sites (Bmax), but not the affinity (KD) on [3H]muscimol binding to subunit combinations
containing α2 subunit (Table 14).
The data of [3H]flunitrazepam binding to membrane preparations of rat brain cortex,
cerebellum and hippocampus was shown in Fig. 19a and 19b. Honokiol showed
inhibitory effects on [3H]flunitrazepam binding to all the three membranes tested (IC50 ∼
200 µM). Magnolol, in the concentration range of 20 µM to 100 µM, showed enhancing
effects on [3H]flunitrazepam binding to the membranes tested. Saturation binding
experiments showed that honokiol (200 µM) significantly decreased binding affinity (3-
5 folds) with slight increase (ca. 1.2 fold) or without changing Bmax, magnolol (60 µM)
slightly increased both the binding affinity (1.5 fold) and Bmax (ca. 1.2 fold) of
[3H]flunitrazepam binding to membrane preparations of rat brain cortex, cerebellum and
hippocampus.
In the preliminary electrophysiological experiments, Sf-9 insect cells expressing human
recombinant GABAA receptors were used. Honokiol (10 µM) showed a similar potency
as compared to diazepam (10 µM), in potentiation of GABA-induced whole-cell
chloride currents in all the subtypes tested αx β2/3 γ2S (X=1,2,3).
In the experiments of [3H]SCH 23390 binding to membrane preparation of rat brain
striata, both honokiol (IC50 of 22 ± 1 µM from three independent experiments) and
magnolol (IC50 of 32 ± 2 µM from three independent experiments) showed inhibitory
effects. In the experiments of [3H]QNB binding to membrane preparation of rat brain
cortex, both honokiol (IC50 of 83 ± 10 µM from three independent experiments) and
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magnolol (IC50 of 76 ± 9 µM from three independent experiments) showed inhibitory
effects.
Figure 17a.
Figure 17a. Effects of honokiol on [3H]muscimol (10 nM) binding to membrane
preparations of rat brain cortex, cerebellum and hippocampus.
 *  P < 0.05, ** p < 0.01 compared to control value (100%).
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Figure 17b.
Figure 17b. Effects of honokiol on [3H]muscimol (10 nM) binding to various
human recombinant GABAA receptor constructed by α, β and  γ subunit
combinations expressed in Sf-9 insect cells by baculovirus.
* P < 0.05, ** p < 0.01 compared to control value (100%)
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Figure 17c.
Figure 17c. Effects of honokiol on [3H]muscimol (10 nM) binding to human
recombinant GABAA receptor subunit combinations of α1β2, α2β3,  expressed in Sf-
9 insect cells by baculovirus.
*  P < 0.05, ** p < 0.01 compared to control value (100%).
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Figure 18a.
Figure 18a. Effects of magnolol on [3H]muscimol (10 nM) binding to membrane
preparations of rat brain cortex, cerebellum and hippocampus.
* P < 0.05, ** p < 0.01 compared to control value (100%).
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Figure 18b.
Figure 18b. Effects of magnolol on [3H]muscimol (10 nM) binding to various
human recombinant GABAA receptor constructed by α, β and  γ subunit
combinations expressed in Sf-9 insect cells by baculovirus.
* P < 0.05, ** p < 0.01 compared to control value (100%).
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Figure 18c.
Figure 18c. Effects of magnolol on [3H]muscimol (10 nM) binding to human
recombinant GABAA receptor subunit combinations of α1β2, α2β3,  expressed in Sf-
9 insect cells by baculovirus.
*  P < 0.05, ** p < 0.01 compared to control value (100%).
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Figure 19a.
Figure 19a. Effects of honokiol on [3H]flunitrazepam (1 nM) binding to membrane
preparations of rat brain cortex, cerebellum and hippocampus.
* P < 0.05, ** p < 0.01 compared to control value (100%).
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Figure 19b.
Figure 19b. Effects of magnolol on [3H]flunitrazepam (1 nM) binding to membrane
preparations of rat brain cortex, cerebellum and hippocampus.
* P < 0.05, ** p < 0.01 compared to control value (100%).
0.001 0.02 0.03 0.1 0.3
0
50
100
150
200
--------------------------------------------------------------------------------------------------
**
**
**
*
**
*
*
Sp
ec
ifi
c 
bi
nd
in
g 
(%
 o
f c
on
tr
ol
)
Concentration of magnolol (mM)
 Cerebellum
 Cortex
 Hippocampus
97
Table 14. Scatchard Plot analysis of the effect of honokiol on [3H]muscimol binding
to various human recombinant subunit combinations of GABAA receptor
expressed in Sf-9/baculovirus system
Subunit
combinations
Control
KD
(nM)
Bmax
(pmol/g protein)
Honokiol
(200 µM)
KD
(nM)
Bmax
(pmol/g protein)
α1β2 13 ± 1 2140 ± 340   5 ± 1 a 3670 ± 330 a
α1β2γ2S 25 ± 2   970 ± 10 10 ± 2 a 1750 ± 100 a
α2β3 15 ± 3 1270 ± 150 11 ± 2 3220 ± 410 a
α2β3γ2S 18 ± 5   932 ± 160 16 ± 5 2970 ± 410 a
Values are expressed as mean ± S.E.M. from 3 estimations on various batches of the
different subunit combinations. KD is the affinity constant of [3H]muscimol binding, the
higher value means the lower affinity. Bmax is the maximum binding sites on the various
subunit combinations for [3H]muscimol binding.
 a  p < 0.05 compared to the relative values in control experiments.
98
The bark of the root and stem of Magnolia species has been used as a folk medicine in
China for the relief of fever, headache, anxiety and nervous disturbance (Fujita et al.,
1972). The two neolignan compounds honokiol (C18H18O2) and magnolol (C18H18O2),
main components of Chinese medicinal plant Magnolia officinalis, were reported to
have many pharmacological activities, such as anti-platelet, anti-microbial, anti-tumour,
insecticidal, anti-asthmatic, anti-oxidant, anti-emetic actions (For review, see Sarker,
1997). Most interestingly, these two compounds also showed some central depressant
effects such as: sedation, ataxia, muscle relaxation as well as having anxiolytic activity
in animal experiments, but the mechanism of action remains unknown (Watanabe et al.,
1983; Maruyama et al., 1998, Kuribara et al., 1998).
The central depressant effects of honokiol and magnolol were first reported by Watanabe
et al. (1983). Magnolol and honokiol produced sedation, ataxia, muscle relaxation in
mice and a dose-dependent loss of the righting reflex in young chickens. Pre-treatment
of mice with magnolol (100 mg/kg) inhibited tonic extensor convulsions and death
produced by an intracerebroventricular injection of penicillin G potassium. It was
concluded that magnolol causes a depression of the ascending activating systems as well
as of the spinal cord. To study the possible mechanism, through which honokiol and
magnolol elicit their central depressant effects, Tsai et al. (1995a) examined the
influence of these two phenolic compounds on 25 mM K+-stimulated release of
[3H]acetylcholine from hippocampal slices of rats. Honokiol, but not magnolol, elicited a
concentration-dependent enhancement of K+-evoked acetylcholine release. Since the
addition of tetrodotoxin, pilocarpine, or methoctramine had no effect on the action of
honokiol, the authors concluded that honokiol enhanced K+-evoked acetylcholine release
directly on hippocampal cholinergic terminals via receptors other than the M2
cholinergic subtypes. The same authors (Tsai et al., 1995b) showed that magnolol (1 ∼
100 µM) had no effect on 5-HT release from rat hippocampal slices but elicited a dose-
dependent inhibition of 5-HT release from cortical slices. The inhibitory effect of
magnolol on K+-stimulated 5-HT release from the cortex was not affected by either
antagonists (metergoline, propranolol and cyproheptadine 0.01 ∼ 10 µM) of various 5-
HT receptor subtypes or by the voltage-dependent sodium channel blocker tetrodotoxin
(1µM). It was concluded that the suppression of brain 5-HT release by magnolol is site-
specific, and the suppression of cortical 5-HT release by magnolol is not mediated by the
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5-HT autoreceptors at the 5-HT terminals. Recently, it was shown that honokiol and
magnolol are the active agents in extracts of Saiboku-to, an oriental herbal medicine.
Mice were treated separately with honokiol and magnolol for 7 days and evaluated by
means of elevated plus-maze test. Honokiol (0.19 mg/kg) is an active anxiolytic agent in
mice and ca. 2 fold more effective than magnolol (0.49 mg/kg). Honokiol is at least 5000
times more potent than Saikoku-to in reducing anxiety in mice as evaluated by elevated
plus-maze (Maruyama et al., 1998). In another study by means of elevated plus-maze
test, honokiol (20 mg/kg) was found having anxiolytic effect, without changing motor
activity (measured by a tilting-type ambulometer with bucket-like Plexiglas activity
cage) or disruption of traction performance (measured by horizontal wire test). The
effect of honokiol was inhibited by flumazenil, (+)bicuculline and caffeine. It was
concluded that honokiol, as compared to diazepam, selectively induces an anxiolytic
effect with less liability of eliciting motor dysfunction and sedation (Kuribara, et al.,
1998), physical dependence, central depression and amnesia (Kuribara et al., 1999).
In our experiments, honokiol and magnolol showed similar effects on [3H]muscimol
binding to various membrane preparations. The comparable enhancing effect of
honokiol and magnolol on [3H]muscimol binding to α1β2γ2S, α2β3γ2S subunit
combinations as well as α1β2, α2β3 subunit combinations, suggests that the presence of γ
subunit in the GABAA receptor complex is not necessary for the action of honokiol and
magnolol on the GABA site.
The significant enhancing effect of honokiol and magnolol on [3H]muscimol binding to
rat brain cortical and hippocampal membranes, as compared to the no enhancing effect
on cerebellar membrane suggested a possible selectivity of these two compounds to
GABAA receptor subtypes. The effect was verified by binding assays of [3H]muscimol
binding to various human recombinant GABAA receptor subtypes, in which a stronger
enhancing effect on [3H]muscimol binding to α2β3γ2S, a significant weaker enhancing
effect to α5β3γ2S subunit combinations were seen. In the saturation binding assays, a
differential effect of honokiol and magnolol on [3H]muscimol binding to different
subunit combinations were also observed. Honokiol changed the number of binding
sites on GABAA receptors constructed by α2β3γ2S and α2β3 subunit combinations,
suggested a non-competitive allosteric modification of the GABA binding site within
the GABAA receptor complex. The changes of both the number of binding sites and the
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binding affinity of [3H]muscimol binding to receptor complexes of α1β2γ2S and α1β2
subunit combinations, suggested a mixture of competitive and non-competitive action of
honokiol. A matching effect was also observed with magnolol (data not shown).
Although honokiol and magnolol showed similar effects on [3H]muscimol binding to
various membrane preparations, differential effects were seen for honokiol as compared
to magnolol on [3H]flunitrazepam binding to membrane preparations of rat brain cortex,
cerebellum and hippocampus. Honokiol markedly decreased the affinity but with slight
increase or without changing the Bmax suggesting mixture action of competitive and
non-competitive modulation on the BZD binding site on the GABAA receptors. For
magnolol there is no competitive action was observed.  These differences indicated a
different mechanism of action of these two isomers on the GABAA receptor complex.
This could possibly explain the different anxiolytic effects of honokiol and magnolol
observed by Maruyama et al. (1998).
In whole-cell patch clamp experiments, the potency of 10 µM honokiol potentiating
GABA-induced chloride current was comparable to that of diazepam with the same
concentration. In binding assays conducted on membrane preparations of rat brain
tissues and the recombinant human GABAA receptor subtypes expressed in Sf-9 insect
cells, 20 µM honokiol and magnolol showed almost no effects. This discrepancy could
be due to differences between the experimental conditions used in binding assays and
functional assays (e.g. the Cl- ion), suggested that honokiol and magnolol could be more
potent interacting with the GABAA receptors in vivo than in vitro.
Since GABA predominantly mediates the inhibition of neuronal transmission, and our
data showed that honokiol and magnolol, by allosteric modification, enhanced the
function of GABA, this could partially explain the central depressant and anxiolytic
effects of honokiol and magnolol. The different behaviour effect of honokiol compared
to diazepam could be that honokiol preferentially interact with some subtypes of
GABAA receptor (e.g. α2 containing receptors), but not the others (e.g. α5 containing
receptors).
Since honokiol and magnolol also interacted with dopamine, serotonin (Tsai et al.,
1995b), acetylcholine (Tsai et al., 1995a) and possibly some other neurotransmitter
receptor systems as well, the in vivo central depressant and anxiolytic effect of them
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could be an overall effects derived from the interaction with the different
neurotransmitter receptor systems.
It would be interesting to determine and compare the differential effect of honokiol and
magnolol on the different binding sites (e.g. GABA sites, BZD sites TBPS site etc.)
presented on the different GABAA receptor subtypes. It is also important to further
investigate the interaction of honokiol and magnolol with other neurotransmitter
receptors.
The effects of honokiol and magnolol on the GABAA receptors have been characterised
using another membrane preparations (EDTA/water dialyzed rat brain membranes), and
the data is being published on Neurochem. Res. (Appendix IV)
4.3.1.4. The isolation and purification of β-carboline derivatives from
Pseudostellaria heterophylla
The proconvulsant β-carboline derivatives were discovered in attempts to isolate
endogenous ligands for BZD receptors. The ethyl ester of β-carboline-3-carboxylic acid
(βCCE) was originally isolated from human urine (see Section 1.2.2.3.). In the
screening of Chinese medicinal plants for compounds having GABAA receptor affinity
in-vitro, we isolated and identified βCCM and βCCE from the root of Pseudostellaria
heterophylla.  Although β-carbolines are well known as BZD receptor ligands, this is to
our knowledge the first report demonstrating a plant origin of these β-carboline-3-
carboxylic acid derivatives.
Batches of totally 10 kg dried roots of Pseudostellaria heterophylla were extracted with
water for ca. 24 hours at room temperature. The extraction was discarded. This
procedure was repeated twice and followed by adding 10 times ethanol (50% v/v) to the
plant root (v/w) and homogenised by an Ultra-Turrax homogeniser. The mixture was
extracted for at least 48 hours. The extractions were terminated by a gravity filtration
(Whatman no. 1 filter paper), followed by a rotary evaporation to remove the ethanol
and water phase to 1/15 of the original volume. The water solution was applied and
gently shook with Chromosorb for 30 min at room temperature. After washing of
Chromosorb with water and ethanol (10% v/v), the [3H]flunitrazepam binding inhibitory
activity was eluted with ethanol (50% v/v) and ethanol (93% v/v). These two ethanol
extracts were evaporated at reduced pressure. The first active fraction (from the ethanol
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(50% v/v) elution of the Chromosorb extraction) were re-dissolved in ethanol (50%
v/v), and applied in batches of 10 ml to a Sephadex LH-20 column (5 × 100 cm). The
Sephadex LH-20 column was first eluted with ethanol (25% v/v) at a flow rate of 1.5
ml/min for 12 hours containing no inhibitory activity. The ethanol elute was discarded.
The column was further eluted in 13.5 ml fractions with ethanol (40% v/v) for 12 hours
and ethanol (50% v/v) for 12 hours. The elute yielded four fractions containing active
compounds on displaying [3H]flunitrazepam binding. Fractions showing inhibition of
[3H]flunitrazepam binding were pooled and freeze-dried.  Fraction No. 1 was re-
dissolved in acetonitrile (CH3CN)/water (25%/75% v/v). Compounds were separated on
a Waters HPLC, C18 Delta-Pak PrepPak 25 × 100 mm plastic reverse phase column, at
flow rate 7 ml/min under linear gradient 25% to 50% CH3CN/75% to 50% water within
50 min using UV detection (210 nm). Fractions with retention times of 22-25 min, 28-
31 min, 36-37 min and 39-41 min contained compounds that showed inhibition of
[3H]flunitrazepam binding. The fractions were pooled and applied to Waters HPLC, C18
Delta-Pak 3.9 × 150 mm analytic reverse phase column at flow 1.2 ml/min using
various isocratic ratios of CH3CN/water. The first two active fractions (F1 and F2) were
purified and the chemical structure of these compounds were identified as the methyl
and ethyl ester of β-carboline-3-carboxylic acid, respectively. The final separation of F1
yielded a single peak at 7 min using isocratic CH3CN/water (28%/72% v/v), and F2 at
10 min using isocratic CH3CN/water (30%/70% v/v). A total of approximate 25 µg of
each of these two active compounds was purified for the structure elucidation. The
chemical structures of purified compounds were identified using NMR spectroscopy
and Mass spectrometry by Prof. Olov Sterner in Division of Organic Chemistry 2, Lund
University, Sweden.
The identical retention time obtained from βCCM and βCCE with F1 and F2,
respectively, under the same condition of the final HPLC step of F1 and F2, supported
the structural identification.
We chose to investigate Pseudostellaria heterophylla, because it was a main element
from a well-known traditional Chinese medicinal prescription named Panacea anti-
epilepsy. As seen by the separation of compounds on HPLC, there are at least 10 or
more active substances that show inhibition of [3H]flunitrazepam binding with similar
potency in-vitro. Although the presence of βCCE could be argued as an artifact of the
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isolation procedure with ethanol (In reality it may not be the case, because the condition
for the formation of βCCE in urine was high temperature and lower pH (Nielsen et al.,
1979; Schmiechen et al., 1993), that does not exist in the isolation of βCCE from
Pseudostellaria heterophylla), the presence of βCCM can not be an isolation artifact. In
addition, the HPLC fractions of extracts of Pseudostellaria heterophylla from
acetonitrile, ethyl acetate, isopropanol and DMSO showed a similar activity (both
retention time and potency) as compared to ethanol extract.
Both βCCM and βCCE are known as potent proconvulsant acting within GABAA/BZD
receptor complex. The plant is used in the reverse pharmacological direction as an anti-
convulsant treatment in traditional Chinese medicine. This raised the intriguing
possibility that some other β-carboline derivatives or other compounds having anti-
convulsant property presence in this plant.
4.3.2 Characterisation of the semi-synthesised derivatives of nature-occurring
compounds (Appendix II)
As we can see from Table 7, the synthetic derivatives of nature-occurring compounds
take a great part of the total nature-originated drugs. Therefore, based on the available
data of nature-occurring compounds to investigate their synthetic or semi-synthetic
derivatives for a possible activity would be a natural consideration. The flavonoids are
the most common constituent occurring in high plants with various biological and
pharmacological properties. Many flavonoids have been purified from plants and were
shown to bind to BZD receptors in the CNS in vitro (for an overview, see Appendix I).
The first BZD receptor active flavonoid described, amentoflavone, as well as another
two flavonoid (dinatin and skrofulein) were isolated from Africa medicinal plants in our
laboratory. Chrysin, apigenin, kaempferol and four other active flavone derivatives were
isolated from Latin American and New Zealand medicinal plants, respectively. In
addition, two semisynthetic flavonoids (6,3’-dinitroflavone and 6-bromoflavone) were
reported binding to BZD receptors with high potency.
In the screening of 32 commercially available flavonoids, seventeen structurally related
flavonoid derivatives are found to inhibit the binding of [3H]diazepam to GABAA/BZD
receptors. 6-methylflavone, the most potent one (IC50 value of 120 nM) was
characterised by binding as well as functional assays. Saturation binding experiments
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showed that 6-methylflavone is a competitive inhibitor of [3H]Ro 15-1788 binding to rat
cortical GABAA/BZD receptors. Combined the data of the GABA ratios for
[3H]diazepam binding to various rat brain membrane preparations and the GABA ratios
for [3H]Ro 15-1788 binding to various recombinant human GABAA/BZD receptor
subunit combinations expressed in baculovirus/Sf9 insect cell system, with the data
obtained from the whole-cell patch clamp on Sf-9 insect cells, we concluded that 6-
methylflavone is most likely a antagonist on the BZD binding site. Meanwhile, based on
available data, some general structure-activity relationship of flavonoids for their
inhibitory effect on the GABAA/BZD receptors have been discussed (Appendix II).
4.4. The blood-brain barrier and bio-availability of CNS active compounds
The blood-brain barrier (BBB) is a unique feature of the CNS, which isolates the brain
from the external environment and prevents the access of the majority of circulating
substances in the blood to the brain (for reviews, see Bonate, 1995; Abbott and Romero,
1996; Bradbury, 1997; Shah and Morradian, 1997; Pardridge, 1998; van de Waterbeemd
et al., 1998; Jolliet-Riant and Tillement, 1999; Rubbin and Staddon, 1999; Saunders et
al., 1999).  The anatomic basis of BBB is the brain capillaries. They are formed by a
complex cellular system including endothelial cells (brain endothelial cells adhere
strongly to each other forming the specific structures called tight junctions, which
prevent cell migration or molecule movement between endothelial cells), basal lamina
(surrounding the endothelial cells on the CNS side, the basal lamina encloses contractile
cells called pericytes which form an intermittent layer and probably play some roles in
terms of phagocytosis activity and defence), astrocytic end feet (almost the entire
surface of brain microvessels is covered with astrocytic feet processes, which build a
continuous sleeve and maintain the integrity of the BBB by the synthesis and secretion
of soluble growth factors essential for the endothelial cells), the perivascular
macrophages and microglia cells.
It is generally accepted that compounds that are unionised at physiological pH,
lipophilic and of low molecular weight (under a 400-600 Dalton threshold) can cross the
BBB by lipid-mediated diffusion. Other compounds as AA, neuropeptides have specific
carrier proteins, which either actively or passively transport these substances into the
brain to ensure that the brain receives the nutrients, and metabolic substrates.
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In general, there are two strategies for increasing the brain availability of drugs. The
first one does not involve modification of the molecule of drugs, including 1). Direct
injection of drugs into the CNS. It could be a useful way of introducing longer acting
slow-releasing preparations, implanted devices etc. 2). Disruption of BBB function.
This can be achieved by e.g. intracarotid arterial injection of a hypertonic solution
mannitol or arabinose etc, which cause endothelial cell shrinkage and opening of the
tight junctions for a period. This technique is only suitable for the acute delivery of
drugs. 3). Reducing the drug efflux from the CNS. This can be achieved by inhibition of
the active efflux mechanisms that are presented at the BBB transporting substances out
of the brain. These efflux systems include the P-glycoprotein and the multidrug
resistance-associated protein. They exhibit very broad substrate specificity and will
pump a wide range of structurally unrelated compounds out of the brain, including some
small molecular size or lipophilic substances. The second strategy for increasing the
brain availability of drugs involves modification of the molecular structure of drugs.
These include 1). Design drugs to utilise the active transport systems which brain uses
for receiving the nutrients. However, because of the high substrate specificity and low
capacity of these inward transport systems, this method may only be suitable for
delivering small quantities of analogues of endogenous substrates (e.g. AA, nucleosides
and peptides). 2). Increasing the lipophilicity of the drugs. Concerning the lipid
pathway, there is a good correlation between in vivo BBB penetration and lipophilicity
(The lipophilicity is classically expressed as its partition coefficient between an organic
solvent, such as octanol, and water) of a drug. Other properties of the drug, such as the
molecular volume, charge of the drug and the extent to which it makes hydrogen bonds
in penetrating the membrane, are also factors contribute to the brain availability of the
drug. Therefore, increasing the lipophilicity of the drug is an important strategy for
increasing the brain availability of the drug. It has been shown that addition of
hydrophobic groups to a molecule may help it to penetrate the brain BBB. The addition
of methyl groups to a series of barbiturates improved their lipophilicity and brain
penetration, leading to increased hypnotic activity. On the contrary, small molecule
permeation through the BBB was decreased for each hydroxyl group added to the
molecule.
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In the current project, we solely characterise the active compounds by in vitro methods.
However, some postulation could be made based on available data. For example,
honokiol and magnolol have been shown having anxiolytic, central depressant effects,
and our experiments showed that they interact with the GABAARs in vitro. Therefore,
these compounds might be able to pass the BBB to exert their CNS effects. It would be
also be interesting to investigate the in vivo effects of phellopterin in the future
experiments.
4.5. Advantages, pitfalls, challenges and the future
Despite of these advantages, there are some inherent pitfalls associated with plant-
derived drug research that could hinder its progress. From our own experiences, there
are several points should keep in mind when carry on the research on active compounds
from plants. 1). Identity of the plants: At the very beginning of the project, when certain
plants were chosen for the screening based on their traditional use, the identity of these
plants could be a key factor determining the later successful isolation. For example, in
TCM, it is quite common that the same name of the herbal medicine could include
several botanically distinct species, e.g. Chinese Baizhi, includes Angelica dahurica,
Angelica anomala, Angelica formosana and Heracleum scabridum four items. The
active compounds of interest could only appear in one of these items. 2). Extraction and
solubility: Since the starting material is a complex mixture of hundreds of compounds, a
suitable solvent is very important. In our project, we usually used 50% ethanol in order
to give consideration both to lipophilic and lipophobic compounds. During the
purification, the solubility of the active compounds could cause some problems,
especially when a trace amount of the active compounds appears in the plant. The
similar solubility of compounds with similar chemical structure in the same plant (and
that is always the case) sometimes can make the separation infeasible. 3). Trace amount
of the active compounds: The isolation, purification as well as structural elucidation
could be a time-consuming and labour-intensive process due to the trace amount of the
interesting compound, moreover, the final isolated compounds could be worthless for
the pharmacologist. It took us more than one year to purified 25 µg of two active
compounds from more than 10 kg Pseudostellaria heterophylla, and the structural
elucidation turn out to be βCCE and βCCM. Although it could be of interest for the
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botanist, it was meaningless for us to go further. 4). Lost activity: It is not the case, the
active compounds could be purified whenever they are found. Usually the screening
started with a small sample of a plant, a large amount of plant is needed to purify
compounds enough for the chemical elucidation. Even with a defined identity,
components of the plant could vary from batch to batch because of the different
processing, different collecting place or season etc. The activity being traced on could
disappear. The biological activity could also be lost during the purification due to
instability of the active compounds or the fact that the activity is a synergistic or
additive effect between several structurally different compounds, whenever they are
separated, the activity is no long there. 5). None interesting activity: Not all activities
found are of interest. In our screening project, almost all the plants showed strong
activity to the GABA binding site. However, since these activities appeared in the first
several fractions from HPLC, we conservatively believe that it could be GABA itself.
Despite of their possible pharmacological significance in their traditional use, we have
to abandon any further investigation. One thing worth a try is to run HPLC under linear
gradient from water, compounds other than GABA should give some more retention
time from the HPLC (see Table 12). 6). False positive activity. Contaminated columns
or other experimental instruments could yield false positive results. To avoid this
happening, a separate set of columns solely used for plant screening would be helpful.
Besides these practical difficulties, from pharmaceutical industry point of view, the
patent protection is weaker for plant-originated drugs; quantitative long-term supply of
botanically well-defined raw materials can be difficult to maintain, especially for
imported items; the structural complexity of the active compound may preclude cost-
effective synthesis (Bruhn, 1989; Nisbet and Moore, 1997). That is why, over the years,
interest of the pharmaceutical industry in natural products as a source of potential, new
chemotherapeutic agents has been deciding. The lead compound generation and drug
discovery processes have been significantly impacted by emerging novel approaches
such as advanced genomics, high-throughput screening, combinatorial chemistry and
biology, and computer-assisted drug design. The role that natural products have played
historically in lead generation is facing a serious challenge (Nisbet and Moore, 1997;
Shu, 1998).
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However, the possible application and integration of new developed technologies, such
as high-throughput screening, combinatorial chemistry and genetic engineering etc., to
natural products research (Nisbet and Moore, 1997), along with its intrinsic advantages,
natural product research, especially these based on ethnopharmacological usage, will
continue to be a active contributing force for new drug discovery, as well as novel
biological tools.
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Chemical structures of compounds
GABAAR agonists (Table 2)
Endogenous
            GABA                                           Taurine                                     β-alanine
Exogenous
Muscimol                                     THIP                            Isoguvacine
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GABAAR antagonists (Table 2)
Competitive
         Bicuculline            Bicuculline methochloride              RU 5135
        Pitrazepin                       (+)-Hydrastine                                 Securinine
                  SR 95531                                                              Benzylpenicillin
                                                (+)-Tubocurarine
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Noncompetitive
           Picrotoxinin                   δ-guanidinovaleric acid                            Enoxacin
         Dimefline                      Pentamethylenetetrazole                    Furosemide
Dopamine 3-o-sulfate                                  m-Benzenesulfonium diazonium chloride
                      Cunaniol                                                                      Norfloxacin
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GABAAR allosteric sites ligands (Section 1.3. ∼ 1.5.)
        TBPS                α-dihydro-picrotoxinin                 Pentobarbital
                   Alphaxalone                                                   Pregesterone
GABAB receptor ligands (Table 1)
                 Baclofen                             Phaclofen                                   Saclofen
GABAC receptor ligands (Table 1)
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Drugs with plant origin (Table 8)
           Atropine                              Caffeine                                       Cocaine
Codeine                               Colchicine                                Ephedrine
           Digitoxin                                                        Digoxin
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                 Gossypol                                                                   Hyoscyamine
                    Kawain                                Levodopa                               Morphine
       Noscapine                       Ouabain                                          Qunine
            Pilocarpine                               Quinidine                              Yohimbine
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                          Reserpine                                                           Scopolamine
                                                  Vinblastine
                                                    Vincristine
Compounds with natural origin as pharmacological tools (Table 9)
Nicotinic AchR ligands
                Nicotine                    Arecoline                                     Physostigmine
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Muscarinic AchR ligands
             Muscarine                                                 Anisodamine
                                Anisodine
Glycine receptor ligand
                                                        Strychnine
Adenylate cyclase and protein kinase C ligand
                  Forskolin                                                          Phorbol
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Compounds isolated from CMH in this project (Table 12)
             Acacetin                            βCCE                                      βCCM
             Honokiol                              Magnolol                                  Rutecarpine
         Saikogenin G                                     Saikosaponin A
OCH3
OH
HO O
O
OH
CH2CH CH2H2C CHCH2
OH
N
N
CO2CH3
N
N
CO2C2H5
H
N
N O
N
OH
CH2CH CH2
OH
CH2CH CH2
HO
CH3
CH3
CH3
CH3 CH3
CH2OH
CH3
O
OH
HOCH2
HO
OH
O
OH
O
OH
HO
CH3
O
O
OH
O
CH3
CH2OH
CH3CH3
CH3
CH3
CH3
155
Drugs or drug candidates from Chinese plants (Table 11)
5,7,3’,4’-tetrahydroxy-flavone-3-nol C4-C8 dimer                      α-dichroine
             β-dichroine                                                                    Agrimophol
              Artemisinin                        Artemether                            Dihydroartemisinin
                        Artesunate                                                                 Arteether
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                 Camptothecin                                                   Ironotecan
                    Curcumol                       Curdione                                  Daidzein
                           Daidzin                                                                   Genistin
              Schisandrin A                     Schisandrin B                           Schisandrin C
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         Schisandrol A                    Schisandrol B                             Schisantherin A
                     Schisantherin B                                              Schisantherin C
                  Homoharringtonine                                              Houttynin
                   Huperzine A                                                           Indirubin
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 Methyl hydroquinone      Nevadensin                                       Piperine
               Rubescensin (oridonin)                                      Pomocodin
                          Triptolide                                            Yingzhaoshu A
           Yuanhucin A
                                                                        Yuanhucin B
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Anti-cancer drugs from plants (Section 3.1.)
                                                           Taxol
                                                                Taxotere
           Podophyllotoxin                                                          Etoposide
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                                                           Teniposide
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